The QualityStocks Daily Tuesday, March 15th, 2022

Today's Top 3 Investment Newsletters

StocksEarning(SONM) $1.2200 +103.33%

QualityStocks(JAGX) $0.5453 +44.53%

SeriousTraders(KAVL) $1.7500 +25.90%

The QualityStocks Daily Stock List

Jaguar Health (JAGX)

QualityStocks, MarketBeat, StockMarketWatch, BUYINS.NET, StreetInsider, InvestorPlace, The Online Investor, StockRockandRoll, Schaeffer's, PennyStockLocks, Penny Stock 101, DreamTeamNetwork, MarketClub Analysis, Promotion Stock Secrets, Wealth Insider Alert, Stock Beast, Trades Of The Day and PoliticsAndMyPortfolio reported earlier on Jaguar Health (JAGX), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Jaguar Health Inc. (NASDAQ: JAGX) (FRA: 1JA2) is a commercial-stage pharmaceuticals firm that is focused on developing and commercializing gastrointestinal products for animals and human prescription use and non-prescription gastrointestinal animal products.

Jaguar Health has its headquarters in San Francisco, California and serves the human and animal health markets across the globe. The firm was established on June 6, 2013 by Lisa A. Conte.

Through its Napo Pharmaceuticals Inc. subsidiary, Jaguar Health Inc. develops and commercializes proprietary human gastrointestinal products. This is in addition to operating through 2 segments: Animal health segment and Human health segment. The former segment commercializes non-prescription and prescription products for production and companion animals while the latter segment develops human products and advertises one of the firm’s products called Mytesi which is used to provide symptomatic relief of non-infectious diarrhea in adults on ARV therapy for HIV/AIDS.

Jaguar Health Inc.’s human products include a crofelemer formulation which is currently undergoing a phase 2 clinical trial for the treatment of irritable bowel, functional/idiopathic diarrhea, congenital diarrheal disorder and short bowel syndrome; crofelemer, which is in its phase 3 clinical trials for supportive care for inflammatory bowel disease and treatment of diarrhea associated with cancer therapy. The firm’s animal products include Neonorm Foal and Neonorm Calf, as well as a non-prescription product for gut health in equine athletes known as Equilevia and an animal prescription drug candidate indicated for the treatment of diarrhea in dogs induced by chemotherapy, called Canalevia.

Jaguar Health Inc. recently incorporated its Napo EU subsidiary in anticipation of its merger with Italian Dragon SPAC, which will broaden the firm’s consumer base overseas and boost growth. The subsidiary will help address the increasing burden of inflammatory diarrhea that has been linked to long-hauler syndrome in the post-coronavirus patient population over in Europe.

Jaguar Health (JAGX), closed Tuesday’s trading session at $0.5453, up 44.5269%, on 37,671,100 volume. The average volume for the last 3 months is 35.509M and the stock's 52-week low/high is $0.343/$6.93.

Sonim Technologies (SONM)

MarketBeat, StockMarketWatch, StockRockandRoll, PennyStockLocks, Penny Stock 101, The Online Investor, QualityStocks and InvestorPlace reported earlier on Sonim Technologies (SONM), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Sonim Technologies Inc. (NASDAQ: SONM) (FRA: 2W9) is engaged in the provision of ruggedized mobile accessories and phones for task workers.

The firm is based in Austin, Texas and was incorporated in 1999 on August 5th by Joakin Wiklund, Sudu Srinivasan, Jai Kumar, Anush Gopalan, Isaac Eteminan and Ram Chandran. Prior to its name change in December 2001, the firm was known as Inc.

The company provides solutions in 3 categories namely, cloud-based software and application services; industrial-grade accessories; and, ultra-rugged mobile devices. It sells accessories, barcode scanners and ruggedized phones through distribution channels in Europe, South America and North America and sells its accessories and mobile phones primarily to wireless carriers in Canada and the U.S. It serves defense, agriculture, transportation, utilities, oil and gas, security and construction industries across the globe.

Its products include a portable communications system dubbed the Rapid Deployment Kit; hands-free in-vehicle voice communication solution, multi-bay charging accessories and remote speaker microphones, which are all industrial grade accessories and the Sonim XP3, XP5s and XP8, which are all based on the android platform and can attach to private and public wireless networks. The enterprise also offers SmartScanner products like an android-based tablet called Sonim RS80 and an LTE device that’s android-based called Sonim RS60.

The company recently entered into a partnership with Business Mobility Partners, a distributor of T-Mobile for business services and products. This move will allow business consumers for T-Mobile to access Sonim’s ultra-rugged devices, which will help extend the firm’s consumer reach and is bound to bring in more investors.

Sonim Technologies (SONM), closed Tuesday’s trading session at $1.22, up 103.3333%, on 90,386,903 volume. The average volume for the last 3 months is 90.387M and the stock's 52-week low/high is $0.475/$10.40.

New Oriental Education & Technology Group (EDU)

Schaeffer's, InvestorPlace, StocksEarning, MarketBeat, MarketClub Analysis, StreetInsider, Zacks,, Trades Of The Day, Market Report, Daily Trade Alert, Street Insider, SmarTrend Newsletters, Uncommon Wisdom, Hit and Run Candle Sticks, InvestmentHouse, Kiplinger Today, The Street, TheStockAdvisors, China Vesting, ChartPoppers, TradersPro, TopStockAnalysts, QualityStocks, Weekly Market Strategies, AllPennyStocks, MarketDNA, Sling-Shot-Stocks, Wealth Insider Alert, The Complete Investor, Leeb's Market Forecast, Investopedia, Investing Lab, Greenbackers, DrStockPick, CRWEWallStreet, Princeton Research, CRWEPicks, CRWEFinance, ChartAdvisor, BUYINS.NET, BestOtc, Barchart, Daily Market Beat, StockHotTips, VectorVest, TradingMarkets, Trading Markets, Top Secret Stocks, Top Pros' Top Picks, The Online Investor, The Best Newsletters, PennyOmega, StockMarketWatch, Investor Ideas, StockEarnings, Stock Tips Network, Short Term Wealth, PROFIT CONFIDENTIAL, PennyToBuck, Penny Sleuth, Money Morning, Millennium-Traders and StreetAuthority Daily reported earlier on New Oriental Education & Technology Group (EDU), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

New Oriental Education & Technology Group Inc. (NYSE: EDU) (FRA: N1U) (HKG: 9901) (BMV: EDUN) is engaged in the provision of private educational services under the New Oriental brand.

The firm has its headquarters in Beijing, the People’s Republic of China and was incorporated in 1993, on November 16th by Yong Qiang Qian and Min Hong Yu. It operates as part of the consumer discretionary industry, under the consumer services sub-industry.

The company operates through the Test Preparation and other courses, K-12 AST and Others segments. It has over 500 firms in its corporate family and mainly serves consumers in China.

The enterprise provides test preparation courses to students who will be taking entrance and language exams used by learning institutions in Commonwealth countries, China and the U.S., as well as after-school tutoring courses for high school and middle school students that help boost exam scores. It also provides online education programs that include pre-school, K-12 and college education; develops and also edits educational materials for test preparation and language training; operates a full-time private secondary and primary school in Yangzhou; and offers language training courses for English and other foreign languages like Spanish, Italian, Korean, French, Japanese and German. In addition to this, the enterprise also provides overseas study tour services and overseas studies consulting services.

As of May 2020, the company offered its programs and services to over 1300 learning centers and 100+ schools. It is focused on expanding to new regions, which will extend its consumer reach and boost its growth, which will encourage more investments into the firm.

New Oriental Education & Technology Group (EDU), closed Tuesday’s trading session at $1.06, up 22.6284%, on 49,675,978 volume. The average volume for the last 3 months is 47.713M and the stock's 52-week low/high is $0.84/$17.68.

RLX Technology (RLX)

Schaeffer's, Trades Of The Day, StocksEarning, QualityStocks, MarketBeat, InvestorPlace and Daily Trade Alert reported earlier on RLX Technology (RLX), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

RLX Technology Inc. (NYSE: RLX) (FRA: 3CM) is an e-vapor firm that is focused on the research, development, manufacture, distribution and sale of e-vapor products.

The firm has its headquarters in Beijing, the People’s Republic of China and was incorporated in 2018, on January 2nd by Yilong Wen, Long Jiang and Ying Wang. It serves consumers in China and operates as a RELX Inc. subsidiary.

The company’s mission is to make RELX a trusted brand for of age smokers via scientific advances, industry-leading technologies and state-of-the-art products, in partnership with committed and talented individuals and firms across the globe.

The enterprise is focused on holistically improving the experience of its adult smokers with their products, which is why it has implemented a multi-layered development framework that encompasses phase-transitions, interactions and accessories. It offers closed-system rechargeable e-vapor products with different value-added features. Its products are mainly sold in its offline retail outlets via its customer representatives, retailers and distributors. The enterprise serves RELX branded partner stores as well as other retail outlets via its distributors.

The firm recently reported its first quarter financial results for 2021, which show a nearly 50% increase in net revenue, in comparison with 2020’s fourth quarter results. Its CEO notes that the firm’s expansion of their distribution network coupled with a strong sequential growth demonstrated sustained user demand for its products. The firm is focused on further expanding its distribution network and enhancing supply chain and production capabilities. This will help extend consumer reach and boost the company’s growth.

RLX Technology (RLX), closed Tuesday’s trading session at $1.71, up 40.1639%, on 86,602,494 volume. The average volume for the last 3 months is 81.607M and the stock's 52-week low/high is $1.16/$20.65.

CooTek (CTK)

MarketBeat, TradersPro, StreetInsider, Trades Of The Day, QualityStocks, Zacks, Wealth Insider Alert, StockMarketWatch and MarketClub Analysis reported earlier on CooTek (CTK), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

CooTek (Cayman) Inc. (NYSE: CTK) (FRA: CT7A) is a mobile internet firm that is focused on the development of innovative mobile applications and AI technology.

The firm has its headquarters in Shanghai, the People’s Republic of China and was incorporated in 2008 by Qiao Ling, Jim Wang, Jia Liang Wang, Teng Ren and Kan Zhang. It serves consumers in China, the U.S. and internationally.

The company’s aim is to empower its users to express themselves and enjoy relevant content without any issues. It acquires users mainly via pre-installations on mobile devices and user downloads from digital distribution platforms. The company generates most of its revenue from the United States.

The enterprise’s main product is an input method for mobile devices dubbed TouchPal Smart Input which generates user interaction data and supports over 100 languages. It also provides a video series which is based on the Fengdu Literature Platform content and IP resources; and a mobile app known as Fengdu Novel, which offers users free online novels. In addition to this, the enterprise also offers educational games like Idiom Hero, puzzle games like Hi Hamster and casual games which include simulation games like Farm Hero. Furthermore, it provides a free pedometer mobile app known as Happy Jogging; a water drink reminder app that helps users drink an adequate amount of water every day; and a fitness application known as Walk Walk.

The company recently launched its audiobook app, dubbed Fengdu Audiobooks, which is equipped with AI technology that supports auto-conversion of texts into audiobooks. Audiobooks have become a popular reading trend and the app, which broadens the various content forms, will help extend the company’s consumer reach, which will prove beneficial to its growth and investments.

CooTek (CTK), closed Tuesday’s trading session at $0.27, up 36.9168%, on 74,159,548 volume. The average volume for the last 3 months is 71.45M and the stock's 52-week low/high is $0.188/$3.4136.

Jianpu Technology (JT)

MarketBeat, Zacks, StreetInsider, TradersPro, QualityStocks and BUYINS.NET reported earlier on Jianpu Technology (JT), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Jianpu Technology Inc. (NYSE: JT) (FRA: JT13) is an open platform that is engaged in the provision of online recommendation and discovery services for financial products.

The firm has its headquarters in Beijing, the People’s Republic of China and was incorporated in 2017, on June 1st by Zheng Yu Wu, Chenchao Zhuang, Cao Feng Liu, Jia Yan Lu and Da Qing Ye. It operates as part of the computer systems design and related services industry. The firm has five companies in its corporate family and serves consumers in China.

The company allows financial service providers with marketing and sales solutions to serve and reach their target consumers more effectively through mobile and online channels. This is in addition to offering users personalized search results and recommendations that have been tailored to fit every user’s credit profile and financial needs, as well as their risk appetite.

The enterprise’s platform enables users access to financial products which include wealth management products, credit cards, consumer and other loans. It also recommends credit cards and loans to individual users. The platform offers integrated, big data risk management, credit underwriting, credit analysis, fraud prevention and detection and sales and marketing solutions mainly to financial service providers.

The company recently received the Specialized Accreditation of Big Data Platform Security from the Zhuoxin Data Program. This certification recognizes the company’s competitive advantage in user privacy protection and data security, which may help bring in more investments into the company as well as facilitate the company’s growth.

Jianpu Technology (JT), closed Tuesday’s trading session at $1.14, up 17.5258%, on 214,411 volume. The average volume for the last 3 months is 214,411 and the stock's 52-week low/high is $0.72895/$3.75.

SPO Networks (SPOI)

We reported earlier on SPO Networks (SPOI), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

SPO Networks Inc. (OTC: SPOI) is a publicly-traded firm which explores potential opportunities and acquisitions in diversified industries.

The firm has its headquarters in Farmington, Arkansas and was incorporated in 1968, on August 26th. Prior to its name change in August 2017, the firm was known as Highline Technical Innovations Inc. The firm serves consumers around the globe, with a focus on the United States.

The enterprise produces a line of hydrogen fuel supplement systems for gas and diesel generators and engines, under its HyImpact line. These systems have been designed to decrease fuel consumption and emissions for oil services, marine and transport applications. It is also involved in the manufacture of off-road vehicles under its HOSS line. The enterprise explores for acquisitions in industries like the construction, general contracting, solid waste and recycling and demolition with waste remediation. In addition to this, it maintains clinically validated marijuana products as well as focuses on recreational and medical marijuana and genetic seed operations. Furthermore, it is also focused on dispensary operations and retail product manufacturing and the development of growing facilities for operations of extraction as well as the wholesale of marijuana and marijuana extracts to licensed wholesalers and retailers.

The company recently launched genetic seed, recreational and medical marijuana operations, with the objective of rapid expansion in the growing marijuana industry, which will not only generate significant revenue and help create value for its shareholders but also extend its consumer reach and bolster the company’s growth considerably.

SPO Networks (SPOI), closed Tuesday’s trading session at $0.001, off by 13.0435%, on 2,219,966 volume. The average volume for the last 3 months is 2.22M and the stock's 52-week low/high is $0.0001/$0.0099.

Nickel Rock Resources (NIKLF)

We reported earlier on Nickel Rock Resources (NIKLF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Nickel Rock Resources Inc. (OTCQB: NIKLF) (CVE: NICL) (FRA: NMK2) is a mineral exploration firm that is focused on acquiring, exploring for and developing exploration targets.

The firm has its headquarters in Vancouver, Canada and was incorporated in 2011, on June 2nd. Prior to its name change in November 2020, the firm was known as Nevada Energy Metals Inc. It operates as part of the other industrial metals and mining industry, under the basic materials sector. The firm serves consumers in the United States and Canada.

The enterprise is primarily focused on exploring for the battery metals required for the electric car market from various mineral resource properties. It is involved in brine-based lithium exploration targets. The enterprise owns a 100% interest in about 75 lithium placer claims which cover more than 640 ha in Clayton Valley. This lithium project is situated near Tonopah, at Silver Peak in the mining-friendly state of Nevada. The enterprise also has an option agreement to earn total interest in the mineral claims held by Klone Group. In addition to this, it has an option agreement to acquire a 100% interest in five mineral claims.

The company is focused on exploring for nickel deposits in an attempt to help meet the demand for nickel from various industries, including the electric car market and electric vehicle manufacturers. The discovery of nickel would not only positively influence its revenues but also encourage more investments into the company as well, which would be good for its growth.

Nickel Rock Resources (NIKLF), closed Tuesday’s trading session at $0.128, up 2.6875%, on 279,532 volume. The average volume for the last 3 months is 279,532 and the stock's 52-week low/high is $0.0577/$0.296.

Link Reservations (LRSV)

TopPennyStockMovers, Pennystockmania, PennyPickGains, MicroCapDaily, Wall Street Mover, The FrontPageStocks, QualityStocks, Promotion Stock Secrets and Insider Financial reported earlier on Link Reservations (LRSV), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Link Reservations Inc. (OTC: LRSV) is a development-stage firm that’s focused on the development and production of CBD products.

The firm has its headquarters in Kington, the United Kingdom and was incorporated in 2006, on December 13th. Prior to its name change in May 2015, the firm was known as Vendum Batteries Inc. It operates as part of the drug manufacturers-specialty and generic industry, under the healthcare sector. The firm serves consumers around the globe, with a focus on the United States and Europe.

The company’s objective is to spread health and joy by bringing a higher level of natural wellness to animals like cats, dogs and horses. It operates through its LinkResPet subsidiary. The company’s products are manufactured from organically grown plants from certified quality hemp farmers that engage in environment-friendly farming.

The enterprise’s products include formulations which address anxiety and comfort, immune system support and allergies, joint and hip mobility and everyday wellness and health for pets. It also develops a hemp-based lotion under its DailyLifeCBD line and is focused on securing varieties of edible and non-edible lifestyle produce for use by humans. This line also offers functional mushroom-infused products. The enterprise’s CBD products for horses focus on herd bound issues, chronic laminitis and equine arthritis while its cat products focus on inflammatory bowel disease, cancer, anxiety, epilepsy and seizures. On the other hand, its dog products focus on obesity and skin conditions and cancer.

The firm is focused on having a stronger presence in retail locations across the United States and eventually in Europe. This will boost product awareness among consumers and improve its revenues significantly, which will benefit its shareholders and encourage more investments into the firm.

Link Reservations (LRSV), closed Tuesday’s trading session at $0.0063, up 7.6923%, on 1,495,900 volume. The average volume for the last 3 months is 1.496M and the stock's 52-week low/high is $0.0021/$0.0685.

Basanite Inc. (BASA)

We reported earlier on Basanite Inc. (BASA), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Basanite Inc. (OTCQB: BASA) is focused on the global basalt fiber reinforced polymer business.

The firm has its headquarters in Oakland Park, Florida and was incorporated in 2006, on May 30th. Prior to its name change in December 2018, the firm was known as PayMeOn Inc. It operates as part of the building materials industry, under the basic materials sector. The firm has six companies in its corporate family and serves consumers in the United States.

The enterprise is involved in the manufacture of lightweight, green and sustainable building products, which include concrete-reinforcing products made from basalt fiber reinforced polymers. Its products include BasaMesh, BasaMix and BasaFlex. BasaMix is a denier basalt fiber which has been developed to absorb the stress linked to settlement cracking in concrete and early-aged plastic shrinkage. It also offers more toughness for enhanced reinforcement and is available in different chopped sizes. BasaMesh is a line of basalt geo-grid mesh roll that’s designed for temperature shrinkage reinforcement. On the other hand, BasaFlex is an enhanced basalt rebar which has been designed as a non-corrosive and sustainable alternative to conventional steel reinforcement. The enterprise provides corrosion-proof reinforcement for industrial and residential basalt slabs on hydraulic structures, grade and precast concrete elements.

The company is focused on entering into strategic supply and distribution agreements to boost acceptance of its products in the construction market and create potential for new orders for its products. This may positively influence the company’s revenues and investments, which will in turn, bolster its growth.

Basanite Inc. (BASA), closed Tuesday’s trading session at $0.204675, off by 16.3739%, on 376,072 volume. The average volume for the last 3 months is 376,072 and the stock's 52-week low/high is $0.0756/$0.6679.

Anebulo Pharmaceuticals (ANEB)

Schaeffer's and MarketBeat reported earlier on Anebulo Pharmaceuticals (ANEB), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Anebulo Pharmaceuticals Inc. (NASDAQ: ANEB) (FRA: 214) is a clinical-stage biotechnology firm that is focused on the development and commercialization of treatments for individuals suffering from substance addiction and acute cannabinoid intoxication.

The firm has its headquarters in Lakeway, Texas and was incorporated in 2020, on April 23rd by Lawyer Joseph F. It operates in the biotechnology industry, under the healthcare sector. The firm serves consumers in the United States.

The company is involved in the development of disruptive treatments for individuals suffering from substance use disorders, including cannabinoid overdose and the extensive addiction landscape. Its objective is to address the unmet needs of these patients.

The enterprise’s pipeline is made up of its lead product candidate, ANEB-001. This formulation has been designed to reverse the negative effects of cannabinoid overdose one hour after it has been administered. The drug’s CB1 antagonists have been designed to bind to the CB-1 receptor, which undoes the actions of cannabinoids like THC (tetrahydrocannabinol). The small molecule cannabinoid receptor antagonist candidate has completed phase 1 trials evaluating its effectiveness. The symptoms and signs of cannabinoid overdose range from sedation to panic and anxiety to psychosis, which is usually accompanied by hallucinations.

The firm is focused on securing financing through the launch of a successful IPO which will help it advance its research as well as help it to better address the significant burden and harm of substance abuse. This will in turn positively impact revenues into the firm and investments, which will bolster company growth.

Anebulo Pharmaceuticals (ANEB), closed Tuesday’s trading session at $6.77, off by 12.0871%, on 2,810 volume. The average volume for the last 3 months is 2,810 and the stock's 52-week low/high is $4.40/$9.33.

Bristol-Myers Squibb Company (BMY)

The Street, StockMarketWatch, Kiplinger Today, MarketClub Analysis, InvestorPlace, Schaeffer's, StreetInsider, MarketBeat, Market FN, The Online Investor, StreetAuthority Daily, StocksEarning, Daily Trade Alert, Top Pros' Top Picks, Zacks, Market Report, The Best Newsletters, Daily Wealth, Trades Of The Day, Stock Research Newsletter, AnotherWinningTrade, Barchart, SmarTrend Newsletters,, Louis Navellier, TopStockAnalysts, Market Intelligence Center Alert, Wealth Insider Alert, Investopedia, Daily Markets, Trade of the Week, Street Insider, Investors Alley, Money Morning, TheStockAdvisor, TheStockAdvisors, TradingMarkets, AllPennyStocks, Dynamic Wealth Report, Uncommon Wisdom, Trading Concepts, Stock Up Featured, Cabot Wealth, Investment U, Profit Confidential, PennyOmega, Dividend Opportunities, Investor Ideas, Trading Markets, 24/7 Trader, TraderPower, Penny Stock Buzz, The Growth Stock Wire, ProfitableTrading, MarketTamer, Investing Signal, The Motley Fool, MarketWatch, PennyToBuck, DrStockPick, CNBC Breaking News, Market Intelligence Center, Investment House, StrategicTechInvestor, The Tycoon Report, Investor Update, INO Market Report, Bull Warrior Stocks, StockTwits, ChartAdvisor, BestOtc, SmallCapVoice, Greenbackers, CRWEWallStreet, QualityStocks, Options Elite, StockHotTips, FNNO Newsletters, FeedBlitz, Darwin Investing Network and CRWEFinance reported earlier on Bristol-Myers Squibb Company (BMY), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Bristol-Myers Squibb Company (NYSE:BMY) traded today at a new 52-week high of $70.19. Approximately 4.1 million shares have changed hands today, as compared to an average 30-day volume of 15.4 million shares.

Bristol-Myers Squibb Company (NYSE:BMY) is currently priced 0.7% above its average consensus analyst price target of $68.95.

In the past 52 weeks, Bristol-Myers Squibb Company share prices are bracketed by a low of $53.22 and a high of $70.19 and is now at $69.42, 30% above that low price.

Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, oncology, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.

Receive IBN Spotlights - "Bite Size" Small, Mid and Large-Cap Technical Indicator Alerts

To stay connected with our complimentary IBN Spotlights, please visit

Bristol-Myers Squibb Company (BMY), closed Tuesday’s trading session at $69.75, up 0.736568%, on 15,978,439 volume. The average volume for the last 3 months is 15.804M and the stock's 52-week low/high is $53.22/$70.19.

The QualityStocks Company Corner

Lexaria Bioscience Corp. (NASDAQ: LEXX)

The QualityStocks Daily Newsletter would like to spotlight Lexaria Bioscience Corp. (NASDAQ: LEXX).

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced that the first phase of its epilepsy research program EPIL-A21-1 is beginning this week. According to the update, the DehydraTECH(TM)-CBD test articles needed to commence dosing have already been manufactured and delivered to the third-party laboratory engaged to complete this research program. EPIL-A21-1 will assess the seizure inhibiting activity of DehydraTECH-CBD compared to the world's only FDA-approved CBD-based seizure medication, Epidiolex(R). Lexaria hopes to demonstrate superior performance based on DehydraTECH’s known advanced drug delivery capabilities. Lexaria's seizure program expects to leverage the significant gains in systemic delivery and brain uptake evidenced and announced from other studies comparing DehydraTECH 2.0 CBD formulations with concentration-matched controls, which the company believes has potential to improve therapeutic efficacy for a range of disease conditions affecting the central nervous system including epilepsy. To view the full press release, visit

Lexaria Bioscience Corp. (NASDAQ: LEXX) is a global innovator in drug delivery platforms. The company’s patented technology, DehydraTECH™, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting healthier oral ingestion methods and increasing the effectiveness of fat-soluble active molecules.  DehydraTECH promotes fast-acting, less expensive and more effective oral drug delivery and has been thoroughly evaluated through in vivo, in vitro and human clinical testing.

DehydraTECH is covered by 21 issued and more than 50 pending patents in over 40 countries around the world. Lexaria’s first patent was issued by the U.S. Patent and Trademark Office in October 2016 (US 9,474,725 B1), providing 20 years of patent protection expiring June 2034. Multiple patents have been awarded since then and are expected in the future.

Lexaria has a collaborative research agreement with the National Research Council (NRC), the Canadian government’s premier research and technology organization. The company has filed for patent protection for specific delivery of nicotine, vitamins, NSAIDs, testosterone, estrogen, cannabinoids, terpenes, PDE5 inhibitors (with brand names like Viagra), tobacco and more.

Lexaria began developing DehydraTECH in 2014 and has since continued to strengthen and broaden the technology. The company has no plans to create or sell Lexaria-branded products containing controlled substances. Instead, Lexaria licenses its technology to other companies around the world to offer consumers the best possible performance across an array of ingestible product formats.

The company’s technology is best thought of as an additional layer that providers of consumer supplements, prescription and non-prescription drugs, nicotine and CBD products can utilize to improve the effectiveness of their own existing or planned new offerings. Lexaria has licensed DehydraTECH to multiple companies, including a world-leading tobacco producer for the research and development of smokeless, oral-based nicotine products, and for use in industries that produce cannabinoid beverages, edibles and oral products.

DehydraTECH is suitable for use with a wide range of product formats including pharmaceuticals, nutraceuticals, consumer packaged goods and over-the-counter capsules, pills, tablets and oral suspensions.

DehydraTECH Technology

Lexaria’s DehydraTECH is designed specifically for formulating and delivering lipophilic (fat-soluble) drugs and active ingredients. DehydraTECH increases their effectiveness and improves the way active pharmaceutical ingredients enter the bloodstream. The major benefits to a subject ingesting a DehydraTECH-enabled drug or consumer product can be summarized by the following:

  • Speeds up delivery – the effects of the product are felt by the subject in just minutes.
  • Increases bioavailability – the technology is much more effective at delivering a drug or product into the bloodstream.
  • Increases brain absorption – animal testing suggests significant improvement in the quantity of drug delivered across the blood-brain barrier.
  • Improves drug potency – more of the ingested product is made available to the body, so lower doses are required to achieve the desired effect.
  • Reduces drug administration cost – lower doses mean lower overall drug costs.
  • Masks unwanted taste – the technology eliminates or reduces the need for sweeteners.

Lexaria has demonstrated in animal studies a propensity for DehydraTECH technology to elevate the quantity of drug delivered across the blood-brain barrier by as much as 1,900 percent, initiating additional new patent applications and opening possibilities for improved drug delivery.

Since 2016, DehydraTECH has repeatedly demonstrated, with cannabinoids and nicotine, the ability to increase bio-absorption by up to five to 10 times, reduce time of onset from one to two hours to just minutes, and mask unwanted tastes. The technology is to be further evaluated for additional orally administered bioactive molecules, including antivirals, cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs) and nicotine.

Market Outlook

Lexaria’s ongoing research and development efforts are mainly focused on development of product candidates across several key segments:

  • Oral Cannabinoids – a market estimated to be worth $18.4 billion in 2021 and expected to reach $46.2 billion by 2025.
  • Antivirals – an estimated $52.1 billion market in 2021 that’s expected to grow to $66.7 billion by 2025.
  • Oral Mucosal Nicotine – smokeless tobacco products, a $13.6 billion market in 2018, is forecast to grow at 7.2 percent annually through 2025.
  • Human Hormones – estrogen and testosterone replacement therapies represented a $21.9 billion market in 2019, with a forecast CAGR of 7.7 percent through 2027.
  • Ibuprofen and Naproxen – NSAID sales totaled $15.6 billion globally in 2019 and are projected to reach $24.4 billion by 2027.
  • Vitamin D3 – the global market size was $1.1 billion in 2021, growing at 7 percent per year and expected to reach $1.7 billion in 2026.

Management Team

Chris Bunka is Chairman and CEO of Lexaria Bioscience Corp. He is a serial entrepreneur who has been involved in several private and public companies since the late 1980s. He has extensive experience in the capital markets, corporate governance, mergers and acquisitions, as well as corporate finance. He is named as an inventor on multiple patent innovations.

John Docherty, M.Sc., is the President of Lexaria. He is a pharmacologist and toxicologist, and a specialist in the development of drug delivery technologies. He is the former president and COO of Helix BioPharma Corp. (TSX: HBP). He is named as an inventor on multiple issued and pending patents.

Greg Downey is Lexaria’s CFO. He has more than 35 years of diverse financial experience in the mining, oil and gas, manufacturing, and construction industries, and in the public sector. He served for eight years as CFO for several public companies and has provided business advisory and financial accounting services to many large organizations.

Gregg Smith is a strategic advisor to Lexaria. He is a founder and private investor with Evolution VC Partners. He is a member of the Sand Hill Angels and held previous investment banking roles with Cowen and Company and Bank of America Merrill Lynch.

Dr. Philip Ainslie serves as a scientific and medical advisor to Lexaria. He is co-director for the Centre for Heart, Lung and Vascular Health, Canada. He is also Research Chair in Cerebrovascular Physiology and Professor at the School of Health and Exercise Sciences, Faculty of Health and Social Development at the University of British Columbia.

Lexaria Bioscience Corp. (LEXX), closed Tuesday’s trading session at $3.14, up 7.9038%, on 25,299 volume. The average volume for the last 3 months is 25,299 and the stock's 52-week low/high is $2.90/$12.50.

Recent News

Cybin Inc. (NEO: CYBN) (OTC: CYBN)

The QualityStocks Daily Newsletter would like to spotlight Cybin Inc. (NEO: CYBN) (NYSE American: CYBN).

Zebrafish share about 70% of the same genes with humans and roughly 85% of human genes known to be linked to human diseases. This makes them a unique model animal for biomedical research, in addition to being social, which makes them suitable for behavioral research into drug discovery and psychiatric disorders. Researchers conducting studies on LSD are microdosing zebrafish in an effort to explore potential new treatments for alcohol use disorder and mental illness. Microdosing refers to ingesting small amounts of a psychedelic. It is believed that microdosing improves open-mindedness, sparks creativity and increases productivity. Many companies, including Cybin Inc. (NYSE American: CYBN) (NEO: CYBN), are also studying other psychedelic compounds such as psilocybin in order to develop treatments for various indications, including mental disorders.

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) is a Canada-based life sciences company focused on the pharmaceutical development of psychedelic products, as well as the functional mushroom market.

The early-stage company boasts an experienced management team featuring industry veterans from pharmaceutical and consumer product backgrounds who have run multiple clinical trials and collectively helped facilitate billions of dollars in product revenues. The team is dedicated to the development of products and protocols within the psychedelic, pharmaceutical and nutraceutical industries.

In particular, Cybin aims to further build upon and expand its intellectual property (IP) portfolio, which is structured around unique psilocybin delivery mechanisms that target a number of different therapeutic indications. In addition, the company has dedicated itself toward furthering its research and IP within the fields of synthetic compounds, extraction methods, the isolation of chemical compounds, new drug formulations and protocol regimes.

Serenity Life Sciences & Natures Journey Inc.

The company’s business model is centered around its two core subsidiaries, Serenity Life Sciences and Natures Journey Inc., which comprise Cybin’s two-pronged approach toward delivering fungi-derived psychedelic and medicinal products.

Serenity Life Sciences is focused on furthering research and development of psilocybin-based medications. Psilocybin is found in certain species of mushrooms and is a non-habit forming, naturally occurring psychedelic compound. Research into psilocybin has shown positive results for the treatment of depression, anxiety, PTSD, addiction, eating disorders, ADHD and other indications.

Natures Journey Inc. operates the Journey brand, which specializes in developing proprietary medicinal mushroom products that target and promote mental wellness, immune boosting detoxification and overall general health and wellbeing.

Partnership with the Toronto Centre for Psychedelic Science (TCPS)

Staying true to its axiom of being a research-first medicinal mushroom life sciences company, Cybin recently announced its entry into a strategic partnership with the Toronto Centre for Psychedelic Science (TCPS), with the goal of furthering its ongoing psilocybin research efforts and expanding Cybin’s psilocybin IP portfolio (

“While there is evidence to support psilocybin as a treatment for certain indications, the Toronto Centre for Psychedelic Science is taking a clinical approach to prove or disprove the safety and efficacy of psilocybin-based microdosing through an open science approach,” Paul Glavine, CEO of Cybin, stated in a news release.

“We are excited to join forces with Cybin and to offer our expertise. A number of firms had approached TCPS, but Cybin demonstrated a superior commitment to high-quality research and integrity in product development. Our high standards for scientific rigor and transparency will find a fitting home within the culture Cybin is cultivating in Canada and abroad,” Thomas Anderson, co-founder of the Toronto Centre for Psychedelic Science, added.

Journey’s Product Monetization & Market Potential for Nutraceutical Supplements

Although Cybin is at the forefront of companies seeking to conduct clinical trials aimed at gaining regulatory approval for psilocybin and other psychedelic products, the company has also placed a great deal of emphasis on generating meaningful revenue from its very outset.

Cybin’s Journey brand has is launching a range of supplements comprised of popular fungi-derived ingredients such as Reishi, Lion’s Mane and Cordyceps. Purported to aid focus and concentration while promoting neurogenesis, Journey’s range of nutraceutical products provides Cybin with a crucial foothold within the non-psychedelic legal supplement market, which is valued at over $25 billion globally and growing at a 9% year-over-year rate.

Pharmaceutical Psychedelics

In addition to the company’s range of non-psychedelic supplements, Cybin has plans to carry out a clinical trial with a new delivery system for its psilocybin-based medications later this year. Ultimately, the company aims to enter into technology transfer agreements with global pharmaceutical companies after phase 1 & phase 2 clinical trials are complete in order to accelerate regulatory approvals in major indications in global markets with entire lifecycle product management.

With products such as psilocybin truffles already legal in nations such as the Netherlands, Jamaica and Bulgaria, Cybin has positioned itself to capitalize on an eventual legalization of psychedelic mushroom-derived products in the future. Working within a regulatory environment with strong similarities to that which dealt with cannabis prior to the industry’s eventual legalization by the Canadian government in 2018, Cybin is laying the groundwork for the moment pharmaceutical psychedelics gain acceptance in North America and abroad.

Amalgamation Agreement and Financing

Cybin recently announced its entry into an amalgamation agreement dated June 26, 2020, with Clarmin Explorations Inc. (TSX.V: CX) and 2762898 Ontario Inc., a wholly owned subsidiary of Clarmin ( Completion of the transactions contemplated in the amalgamation agreement will result in the reverse takeover of Clarmin by Cybin.

In connection with the proposed transaction, Cybin plans to complete a “best-efforts” brokered private placement of subscription receipts of Cybin, with a syndicate of agents co-led by Stifel Nicolaus Canada Inc. (Stifel GMP) and Eight Capital, to raise a minimum of C$14 million ($10 million) and a maximum of C$21 million ($15 million), with a 15% agents’ option.

To date, Cybin has raised approximately C$10,400,000 through an initial financing round and its series A financing round.

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN), closed Tuesday’s trading session at $0.7842, up 0.538462%, on 239,984 volume. The average volume for the last 3 months is 232,080 and the stock's 52-week low/high is $0.7738/$3.38.

Recent News

CNS Pharmaceuticals Inc. (NASDAQ: CNSP)

The QualityStocks Daily Newsletter would like to spotlight CNS Pharmaceuticals Inc. (NASDAQ: CNSP).

A new study has found that young men have a heightened risk of death from central nervous system cancer regardless of the cancer treatment they undergo. Central nervous system cancer is one of the top five cancers diagnosed in young adults. It develops when abnormal cells form in the tissues of an individual’s spinal cord and/or brain. The presence of some genetic syndromes also increases the risk of an individual being diagnosed with a central nervous system tumor. However, males need not despair if they are diagnosed with a CNS cancer; several companies, including CNS Pharmaceuticals Inc. (NASDAQ: CNSP), are hard at work seeking better treatments for brain cancer so that patients can attain worthwhile clinical outcomes when diagnosed and commence treatment.

CNS Pharmaceuticals Inc. (NASDAQ: CNSP) is a clinical stage biotechnology company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system.

The company was founded in 2017 and is headquartered in Houston, Texas.

Organ Targeted Therapeutics

The company’s lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. Berubicin also has potential to treat other central nervous system malignancies. Based on limited clinical data, Berubicin appears to be the first anthracycline to cross the blood brain barrier in the adult brain, and it was the subject of a successful Phase 1 study which found the MDT and produced efficacy data as well.

CNS holds a worldwide exclusive license to the Berubicin chemical compound. The company has acquired all requisite data and know-how from Reata Pharmaceuticals Inc. related to a completed Phase I clinical trial of Berubicin in malignant brain tumors. In this trial, 44% of patients experienced a statistically significant improvement in clinical benefit. In 2017, CNS entered into a collaboration and asset purchase agreement with Reata.

CNS intends to explore the potential of Berubicin to treat other diseases, including pancreatic and ovarian cancers and lymphoma. The company is also examining plans to develop combination therapies that include Berubicin.

CNS estimates that more than $25 million in private capital and grants were invested in Berubicin prior to the company’s $9.8 million IPO in November 2019.

CNS intends to submit an IND for Berubicin during the fourth quarter of 2020 and expects to commence a Phase II clinical trial of Berubicin for the treatment of GBM in the U.S. in Q1 2021. A sub-licensee partner was awarded a $6 million EU/Polish National Center for Research and Development grant to undertake a Phase II trial of Berubicin in adults and a first-ever Phase I trial in pediatric GBM patients in Poland in 2021.

The company’s second drug candidate, WP1244, is a novel DNA binding agent licensed from the MD Anderson Cancer Center. In preclinical studies, WP1244 proved to be 500-times more potent than the chemotherapeutic agent, daunorubicin, in inhibiting tumor cell proliferation. The company has entered into a sponsored research agreement with the MD Anderson Cancer Center to further the development of WP1244.

CNS Pharmaceuticals recently engaged U.S.-based Pharmaceutics International Inc. and Italian BSP Pharmaceuticals SpA for the production of the Berubicin drug product. The company has implemented a dual-track manufacturing strategy to mitigate COVID-19-related risks, diversify its supply chain and provide for localized availability of Berubicin. CNS has already completed synthesis of Berubicin’s active pharmaceutical ingredient (API) and has shipped the API to both manufacturers in order to prepare an injectable form of Berubicin for clinical use.

Global Brain Tumor Therapeutics Market

The high recurrence rate of malignant brain tumors is due to reappearance of focal masses, indicating that a sub-population of tumor cells in these cancers may be insensitive to current therapies and may be responsible for reinitiating tumor growth. This necessitates the development of newer drugs in the market that demonstrate greater efficacy in treating such aggressive cancers.

A global increase in neurological disorders has placed increased attention on cancers of the brain over the past decade. Neurological disorders are becoming one of the most prevalent types of disorders, due to longer life expectancy, greater exposure to infection and an increasingly sedentary lifestyle. Because few treatments for primary and metastatic cancers of the brain exist, costs are high and have acted as a restraint for the brain tumor therapeutics market.

Despite progress in surgery, radiotherapy and chemotherapeutic strategies, effective treatments for brain cancer are limited by a lack of specific therapies for the brain and the difficulty in transporting therapeutic compounds across the blood brain barrier. Therefore, there is a significant need for novel and effective therapeutic drugs and strategies that prolong survival and improve quality of life for brain tumor patients.

Several companies are making significant investments into R&D, which is expected to bring more treatment options to the market in the near future. Industry reports consistently project continued growth in the market.

One report estimates that the global brain tumor therapeutics market will reach a valuation of $2.74 billion in 2023, with the market expected to register a CAGR of 11% during the forecast period from 2018 to 2023. Another report projects that the global brain tumor therapeutics market will reach $3.4 billion by 2025, up from $2.25 billion in 2019 (

Management Team

John M. Climaco is the CEO of CNS Pharmaceuticals. For 15 years, Climaco has served in leadership roles for a variety of health care companies. Recently, Climaco served as the Executive Vice President of Perma-Fix Medical S.A, where he managed the development of a novel method to produce Technitium-99. Climaco also served as President and CEO of Axial Biotech Inc., a DNA diagnostics company. In the process of taking Axial from inception to product development to commercialization, Climaco forged strategic partnerships with Medtronic, Johnson & Johnson and Smith & Nephew.

Christopher Downs, CPA, is the company’s Chief Financial Officer. Downs previously served as Interim Chief Financial Officer and Executive Vice President of InfuSystem Holdings Inc. (NYSE: INFU), a supplier of infusion services to oncologists in the United States. Downs holds a Bachelor of Science from the United States Military Academy at West Point, an MBA from Columbia Business School and a Master of Science in Accounting from the University of Houston-Clear Lake.

Dr. Donald Picker is the Chief Scientific Officer of CNS. Picker has over 35 years of drug development experience. Prior to joining CNS, Picker worked at Johnson Matthey, where he was responsible for the development of Carboplatin, one of the world’s leading cancer drugs, which was acquired by Bristol-Myers Squibb with annual sales of over $500 million. In addition, he oversaw the development of Satraplatin and Picoplatin, third-generation platinum drugs currently in late-stage clinical development.

Sandra L. Silberman, M.D., Ph.D., is the Chief Medical Officer of CNS Pharmaceuticals. Silberman is a hematologist/oncologist who earned her B.A., Sc.M. and Ph.D. from the Johns Hopkins University School of Arts and Sciences, School of Public Health and School of Medicine, respectively, and her M.D. from Cornell University Medical College. She then completed both a clinical fellowship in hematology/oncology and a research fellowship in tumor immunology at the Brigham & Women’s Hospital and the Dana Farber Cancer Institute in Boston, Massachusetts. Silberman has played key roles in the development of many drugs, including Gleevec(TM), for which she led the global clinical development at Novartis. Silberman advanced several original, proprietary compounds into Phases I through III during her work with leading biopharmaceutical companies, including Bristol-Myers Squibb, AstraZeneca, Imclone and Roche.

CNS Pharmaceuticals Inc. (NASDAQ: CNSP), closed Tuesday’s trading session at $0.3203, up 4.9476%, on 637,865 volume. The average volume for the last 3 months is 636,795 and the stock's 52-week low/high is $0.2453/$3.24.

Recent News


The QualityStocks Daily Newsletter would like to spotlight SPYR Inc. (OTCQB: SPYR).

  • Applied Magix's latest product, the MagixStatus cables are expected to be ready for shipment and delivery within 30 days
  • The new advisory board to be announced in the near future will guide Applied Magix on its journey toward expansion
  • SPYR has updated its branding to reflect the fresh and dynamic attitude that the company wishes to convey to consumers

SPYR (OTCQB: SPYR), dba SPYR Technologies, a technology company that develops and resells Apple(R)-ecosystem-compatible products for the multibillion-dollar Internet of Things (“IoT”) Smart Home and Connected Car markets, through its subsidiary Applied Magix inc., recently announced multiple significant milestones achieved in Q1 2022. Most notably, the company opened up pre-orders for a new and exciting product, the MagixStatus Cables; it has created an advisory board for expansion efforts; and it has implemented a series of branding changes to reflect the company's current and future direction. SPYR is continuing to identify and target acquisitions to enable the company's growing footprint in the industry while expanding its product offering to consumers, including artificial intelligence (“AI”) and smart technology products. SPYR (OTCQB: SPYR), dba SPYR Technologies, a technology company and its subsidiary, Applied Magix Inc., have appointed a new advisory board member. Fred Tio, a former senior creative director of Worldwide Marcom, Apple Inc., has accepted an invitation to serve on the Applied Magix advisory board. Applied Magix develops and resells Apple(R) ecosystem-compatible products in the growing multibillion-dollar IoT smart home and connected car markets. According to the announcement, Tio is looking forward to bringing his Apple experience and passion to the Applied Magix line of products. The company noted that Tio’s influence will be felt on the development and expansion of Applied Magix and its ecosystem of Apple-compatible products moving forward. “What a pleasure to have Fred Tio on our advisory board, and to have his experience and advice to help us grow,” said Applied Magix CEO Dr. Harald Zink in the press release. “We have worked together in our various prior lives, and it will be great to be working with Fred once again.” To view the full press release, visit

SPYR Inc. (OTCQB: SPYR), dba SPYR Technologies, is a technology company which, through its Applied MagiX Inc. subsidiary, develops and resells Apple®-ecosystem-compatible products with an emphasis on the growing, multibillion-dollar Internet of Things (IoT) Smart Home and Connected Car markets.

SPYR continues to identify and target acquisitions with an aim of growing its footprint in the industry and expanding the products it offers consumers, including companies developing artificial intelligence and smart-technology products. In 2020, SPYR acquired Applied MagiX Inc., a registered Apple developer and reseller of Apple ecosystem compatible products with an emphasis on the smart home market, as a wholly owned subsidiary. Applied MagiX operates in the IoT market and, more specifically, the segment of the market related to the development, manufacture and sale of devices and accessories specifically built on Apple’s HomeKit® framework. These products work within the Apple HomeKit ecosystem and are exclusive to the Apple market and its consumers.

Initially, while working to develop, manufacture and sell its own line of branded products, Applied MagiX will be sourcing HomeKit products and accessories from worldwide manufacturers, vetting and selecting best-of-breed products, selling them directly to consumers and supporting them. The company focuses on Apple consumers – a target market with higher disposable income and a demonstrated willingness to pay a premium for quality products. On average, Apple product users spend roughly twice as much on technology as other smartphone users. Those who purchase smart home products spend more than $3,000 on average.

By creating smart hardware and software solutions exclusively for Apple consumers, SPYR addresses a problem faced by that market – having few “smart” devices that integrate with Apple’s HomeKit, despite being the most affluent and loyal consumers of tech products.


The company’s Applied MagiX subsidiary offers multiple product lines to its target markets. First, the subsidiary is a reseller of third-party manufactured Apple HomeKit and Apple CarPlay compatible products. HomeKit comes pre-installed on every new iPhone, while the CarPlay platform is licensed by all major auto manufacturers. Applied MagiX identifies white label products, applies the company’s branding, improves the software and sells these improved products to consumers. Finally, Applied MagiX is developing its own proprietary line of smart home and connected car products, including Apple-compatible home cameras, sensors and alarms, as well as additional Apple-compatible smart car products in the iOS ecosystem.

Among the subsidiary’s products sold to consumers are:

  • The MagixDrive Wireless CarPlay adapter, which allows users to access CarPlay wirelessly using their iPhones
  • The HomeKit Secure Video Camera with iCloud Storage
  • The Multipurpose Sensor with Alarm
  • The Environment and Motion Sensor
  • The Window and Door Contact Sensor

Market Outlook

According to Statista, the global smart home market is expected to generate revenue of more than $104 billion in 2021. The market is forecast to hit more than $187 billion in revenue by 2025, recording a CAGR of 15.75 percent.

The number of active households in the worldwide smart home market is expected to reach nearly 500 million by 2025. Household penetration is just over 12 percent in 2021 and is projected to nearly double by 2025 to more than 22 percent.

Allied Market Research valued the global connected car market at more than $63 billion in 2019 and projected a CAGR of 17.1 percent, which would push revenue to more than $225 billion by 2027. Allied identified rising consumer demand for connectivity solutions, surging need for constant connectivity, increasing dependency on technology and an upsurge in tech-savvy population as key factors driving the projected growth of the connected car market.

Management Team

James R. Thompson is the CEO, President and General Counsel of SPYR. Over the past 28 years, Mr. Thompson has deftly managed a colorful spectrum of legal clients and situations. In the process, he has helped many companies – both large and small – thrive. Now he welcomes the challenge to take the company and his career in an entirely new direction. A native of Philadelphia, he holds a J.D. from Rutgers University and a Bachelor of Science from the University of Denver.

Jennifer Duettra is the Executive Vice President of SPYR. She brings a great deal of knowledge in mobile gaming and pop culture to the company. She is an attorney and was thrilled by the prospect to combine her law experience with a chance to be creative. She is a native of Colorado and received her Bachelor of Arts in Political Science and Speech Communication from Colorado State University. She holds a J.D. from Harvard University.

Trang Nguyen is the CFO of SPYR. From 2019 to 2020, she served as the Financial Reporting Manager for Del Taco, where she was responsible for the preparation and filing of periodic financial reports with the U.S. Securities and Exchange Commission. From 2016 through 2019, Ms. Nguyen was Accounting Manager for Pinnacle Tax Accounting in Los Angeles, California. She was a part of Ernst & Young’s audit team in Los Angeles from 2006 to 2008, leading engagements on interim and year-end ad SOX 404 auditing procedures for major enterprise accounts. Ms. Nguyen holds a Bachelor of Art, Business Economics (Minor in Accounting) from the University of California, Los Angeles. She is a certified public accountant with an inactive license.

Dr. Harald Zink is the CEO, Founder and Chief Product Architect of SPYR subsidiary Applied MagiX. Prior to founding Applied MagiX, he was Director of Technologies and later Vice President of Technologies at Sarkissian Productions in Los Angeles. He also served as Director of Technologies at SMZ Technologies and, for more than 17 years, as Macintosh Technology Consultant to The Walt Disney Studios in Burbank, California. He speaks five languages and holds degrees from the University of California, Riverside.

Kelly Clark is the COO of Applied MagiX. Before joining the subsidiary, he worked as Vice President of Sales Operations at TruClear Global. Prior to that, Mr. Clark was Senior Director of Program Management at Pacific Group Ventures and Operations Manager at Barco. He has also held operations management positions at Deluxe Digital Studios and Sony Pictures Entertainment. Mr. Clark holds a bachelor’s degree in international business from the University of Southern California.

SPYR Inc. (OTCQB: SPYR), closed Tuesday’s trading session at $0.049, up 22.5%, on 5,356,569 volume. The average volume for the last 3 months is 5.357M and the stock's 52-week low/high is $0.02355/$0.231.

Recent News

Hollywall Entertainment Inc. (OTC: HWAL)

The QualityStocks Daily Newsletter would like to spotlight Hollywall Entertainment Inc. (OTC: HWAL).

  • Hollywall formed a new R&D division to explore the use of cryptocurrency technologies, token omics, NFTs, and the blockchain
  • The company is working on the HW Network digital delivery platform, a revolutionary digital distribution and verification system designed to maximize quality control, revenues for creators and copyright owners, and customer delivery
  • NFTs have garnered a lot of interest and have provided a different avenue for fans to support artists directly
  • Hollywall’s foray into music NFTs fulfills its commitment to empowering creatives as well as offering value

Interest in non-fungible tokens (“NFTs”) ballooned in 2021, resulting in unprecedented growth in NFT sales to $25 billion in 2021, up from just $95 million a year earlier ( The buzz around NFTs percolated different sectors, reaching the ears of both laypeople and experts and, as a result, earning recognition as 2021’s word of the year, according to the Collins Dictionary ( Still, as a recent Forbes article notes, NFTs have the potential to disrupt vast swaths of industries and sectors (

Hollywall Entertainment Inc. (OTC: HWAL) is a telecommunication, media, technology, broadcasting and entertainment company. Through various subsidiaries, Hollywall maximizes rights to its music, film, television, software and game libraries. Hollywall owns exclusive and nonexclusive rights to market, manufacture and distribute music master recordings performed by multiple platinum-selling acts.

Hollywall was founded in 2009. The company currently has two corporate offices – one in Washington D.C. and the other in New York City.

Hollywall Entertainment Inc. (Hollywall) Subsidiaries

Hollywall has a portfolio of operating subsidiaries spanning various industries, including infrastructure development, 5G and telecommunications, broadcasting, education, media and entertainment.

Hollywall is a minority majority-controlled consortium enterprise company led by founder and President/CEO Darnell Sutton, a highly recognized visionary and award-winning business and social leader.

HWAL continues to expand its business enterprise to numerous city and state municipalities and government agencies throughout the country, including: Washington DC, New York, Virginia, Massachusetts, Pennsylvania, Texas and California, as well as within the Blackbelt regions of Alabama, Louisiana, Mississippi, Georgia and North Carolina, leading the way in developing and implementing solutions to work toward closing the broadband digital divide that has been forced upon the most vulnerable in underserved urban and rural communities nationwide.

Hollywall Development Company (“HWDC”)

HWDC builds, restores and creates “smart” cities/communities and fiber networks throughout the U.S. HWDC services, initiatives and investments include broadband and 5G networks, IOT, smart city technologies, energy, tele-medicine, tele-education, transportation, clean water, waste management and the development of green environments.

HWDC employment growth opportunities continue to attract the industry’s best, brightest and most seasoned corporate executives to join its staff, as well as its ongoing efforts to develop highly effective and profitable strategic partnerships with investment banks, global capital funds, public financial and wealth management firms, construction and engineering companies, telecommunications companies, federal agencies, state and local governments, nonprofits, faith-based organizations and housing authorities.

HWDC’s Smart Cities division aims to provide various services and solutions, such as fiber-optic networking, data centers, smart kiosks, charging stations, security and camera systems, smart traffic monitoring, emergency alert systems, gunshot detection, backup power solutions, smart connected buildings, connected and autonomous vehicles, intelligent transportation systems, advertising and more.

HW Vision and Omnipoint Technology Inc.

Hollywall Entertainment advanced its technological footprint by acquiring top United States telecommunications firm Omnipoint Technology Inc. in 2020. Through the formation of a new wholly owned subsidiary, HW Vision, Hollywall intends to offer state-of-the-art services in the continuously growing digital marketplace, such as:

  • 5G and Fiber Network installation services
  • Affordable high-speed internet access
  • Telehealth services
  • Domain hosting
  • Web conferencing
  • Managed internet services
  • Nationwide unlimited talk, text and data cellphone plans
  • Video broadcasting

In conjunction with its Omnipoint Technology partner, HW Vision has created and developed unique branding for streaming media programming, live television and on-demand content. Offerings from the HW Vision brand are expected to be available for purchase early in 2021.

Hollywall Entertainment Digital Music Network and Hollywall TV

The Hollywall Entertainment Digital Music Network (“HW Network”) has been constructed to sell single song downloads, artist album downloads and ringtones, as well as licensing music for commercial use. Hollywall Music is an owner of legacy music and video collector sets that are distributed to retail, wholesale and download or streaming services. This music library has been protected for over 20 years, and it contains some of the rarest and most coveted unpublished records by legends in the music industry.

Market Outlook

Covering various industries that are continuously expanding, such as telecommunications, media, technology, construction, infrastructure, entertainment and broadcasting, Hollywall is uniquely positioned to secure a prominent role and leverage continued growth opportunities for its subsidiaries.

The 5G sector alone could generate significant interest and market opportunities for Hollywall via HWDC and its community-focused initiatives, including the development of smart cities. The global 5G market was estimated at $41.48 billion for 2020 and is expected to reach an impressive $414.5 billion by 2027, expanding at a CAGR of 43.9% (

Management Team

Darnell Sutton is the Founder, CEO and Chairman of Hollywall Entertainment Inc. Mr. Sutton has over 40 years’ experience with many talents and vast experience as a veteran in the music recording industry, publishing, distribution, live entertainment, television, broadcasting, film and sports athlete, TV/film celebrity and artist management.

Darnell Sutton has represented and worked with some of the greatest athletes and entertainers of our time, including the “King of Pop” Michael Jackson, former heavyweight boxing champion Mike Tyson, current Welterweight Boxing Champion Floyd Mayweather, tennis superstar Serena Williams, Julius “Dr. J” Erving and incomparable multiple Grammy award-winning performers such as The Jacksons, Patti Labelle, Roberta Flack, MC Hammer, Dionne Warwick and Mariah Carey… just to name a few.

“Darnell Sutton, is one of the most exciting master communicators, creative developers and innovators of our time”…says, Tom Stein, Success Magazine.

“After many years of developing, producing and acquiring some of the world’s finest entertainment properties, we are honored to present Hollywall Entertainment companies to the marketplace. We are thrilled to join forces and work with some of the most brilliant and talented Hollywood and Wall Street executives, who have a combined shared experience of industry-recognized excellence,” Sutton said in a news release.

Roxanna Green is the Chief of Staff for Hollywall Entertainment Inc. She has over 30 years of diverse background experience ranging from corporate management to finance. Her experience includes providing corporate legal and financial guidance to both public and private companies, as well as spearheading audits, merger and acquisition negotiations, branding, marketing and public relations initiatives. She has spent the majority of her 30 years in the entertainment and media industry. She has worked with diverse institutions such as banks and securities firms, among others.

Hollywall Entertainment Inc. (OTC: HWAL), closed Tuesday’s trading session at $0.955, up 0%, on  volume. The average volume for the last 3 months is 100 and the stock's 52-week low/high is $0.51/$3.975.

Recent News

RYAH Group Inc. (CSE: RYAH)

The QualityStocks Daily Newsletter would like to spotlight RYAH Group Inc. (CSE: RYAH).

RYAH Group (CSE: RYAH) today announced that its subsidiary, RYAH Medtech Inc., has received a medical device certification in New Zealand for its proprietary Internet of Things (“IoT”) powered medical cannabis inhaler, proprietary cartridges and software application associated with the device (the “RYAH Smart Medical Inhaler System”). This comes in coordination with Medical Kiwi Ltd. as local sponsor for the New Zealand certification. Medical Kiwi is a New Zealand-based leader in R&D, manufacturing, cultivation and distribution of medical cannabis and medical devices. “We are pleased to continue gaining traction with medical device registration around the world and are excited to begin our commercial strategy with Medical Kiwi in New Zealand,” said Gregory Wagner, CEO of RYAH Group. “Medical Kiwi's patient distribution access combined with RYAH's Smart Medical Inhaler makes the perfect combination for providing safe, informed medical therapies to the patient community in New Zealand.” To view the full press release, visit

RYAH Group Inc. (CSE: RYAH) is a leading digital health care analytics and technology company with a mission to advance the world’s transition to remote-health solutions and data analytics in patient treatments. Through the company’s IoT dose-measuring devices and AI analytics, RYAH is reshaping understanding of the value of devices combined with data, to positively impact the future treatment of patients for various medical conditions.

The company is a leading developer of dose-measuring IoT devices connected with its turn-key platform designed to aggregate and correlate HIPPA-compliant data, suitable to all participants in the patient treatment cycle. The company also specializes in customized, fully integrated, mobile applications and APIs, specifically designed to meet the needs of clinics, clinical trials, government and university research centers, for experimentation and treatment validation – significantly reducing variations in patient-related trials. RYAH unlocks data in the complete therapeutic plant lifecycle – from seed to consumption.

Since it began developing and commercializing its smart inhaler solution in 2018, the company has evolved a complete IoT device and data analytics platform that includes multiple delivery mechanisms, designed to capture anonymous patient dosing and feedback, combined with detailed strain analytics, enabling customized dosing regiments. The company has secured numerous partnerships across the globe, including establishing a footprint in the UK, USA, Australia and Canada, and it has closed several deals in the European Union, as well. The company’s Smart-Inhaler has been selected as the dose-measurement, dose-control and data analytics platform for a UK pain management study and one of the world’s most ambitious and largest clinical trials ever to be conducted in cannabis.

Product Portfolio

The company’s current portfolio incorporates an ecosystem of IoT products, each consisting of three elements: the device, the medicine-carrying component and the mobile application. The product line currently includes a Smart Dry-Herb Dose-Measuring Inhaler in the commercial stage, a Smart Transdermal Patch in the production stage and a Smart Liquid Dispensing Pen in the prototype stage.

RYAH Smart-Inhaler

The RYAH Inhaler is the first dry-herb inhaler that allows users to track and control how much is inhaled, providing consistent and predictable results. This inhaler connects with the RYAH Health App, which features stat-tracking and presets for temperatures and dosages, all of which can be customized to individual needs and doctor recommendations, as well as a post-session review mechanism that allows the collection of session data and feedback for further efficacy analysis for customized dosing capabilities.

RYAH’s proprietary stainless-steel cartridges for the inhaler use QR technology that contains lab testing and grower information pertaining to the specific strain, thereby mitigating elicit product use and enabling completely transparent remote medicinal analytics, from seed to consumption.

In addition, the RYAH Cartridges provide a unique closed-loop recurring revenue opportunity for the company, as the RYAH Inhaler only works with this type of proprietary cartridges that licensed partners fill with medicine. The partners benefit from all the back-end data, providing them access to consumption habits, statistics and other data on patient preferences.

RYAH Smart-Patch

The RYAH Smart Transdermal Patch is a lightweight, reusable, mobile-controlled patch used for site-specific therapies. The Patch is an Electronic Topical Delivery Patch system intended for recommendation and administration by pain relief professionals and physical and occupational therapists. The patch data and the heating element is completely IoT and controlled by RYAH’s proprietary smartphone applications, which allows scheduling and ‘boosting’ medicine release, on-demand.

RYAH Smart-Pen

The RYAH Pen is an app-controlled liquid dispenser designed to provide a precise mix of up to three medicine components to create an ‘entourage effect’, enabling customized, wide-spectrum recommendation opportunities by licensed clinicians. The Smart-Pen will feature cartridges that contain CBD, THC and other isolates such as flavonoids or vitamins, or other solutions. There is a built-in mechanism designed to control usage based on recommended dosing schedules.


RYAH MD serves as a remote and interactive patient-doctor collaboration and dosing administration platform. Doctors can remotely set dosage amounts for their patients, creating digital prescriptions for the RYAH IoT devices and tracking patient usage in real-time. RYAH MD offers features that include real-time monitoring, appointment booking, doctor-patient video calls and science-based strain recommendations, as well as promoting a better understanding of the effects and benefits of those recommendations among patients. Information is gathered from all of the RYAH devices.

PotBot App

The PotBot App is a medical cannabis education mobile application that leverages patented AI technology to capture structured and unstructured data to assist patients in learning about various treatments in plant-medicine based on their efficacy goals. The PotBot App is currently one of the top-rated medical cannabis educational mobile applications on the Apple App Store in the United States, with over 300,000 downloads.

Through the combination of peer-reviewed and empirical data, the PotBot App provides detailed information on the targeted and tested cannabinoid levels and associated strains from cannabis patients. The result is personalized and driven by data to inform patients of potential product matches associated with similar ailments and efficacy goals.

Market Outlook

RYAH holds a unique position in the $100.3 billion medical plant market, with the potential to capture and capitalize on growth opportunities made available by both the IoT and Data Intelligence sectors.

In 2018, the global IoT market was valued at $212.1 billion, and it is expected to grow exponentially to $1.3 trillion by 2026, registering a CAGR of 25.68%, according to Verified Market Research (

Management Team

Dr. Boris Goldstein, Ph.D., is the founder and Chairman of RYAH Group. He is a seasoned entrepreneur, investment banker and venture capitalist. He started his career as the founder of Software House HT, which grew into a worldwide corporation with over 40 offices in 17 countries. Since then, Goldstein has founded and served on the boards of directors and advisory boards for numerous companies in Silicon Valley and Silicon Alley. Goldstein brings experience in fundamental research, investment and technology, authoring multiple patents and books.

Gregory Wagner, MBA, is Chief Executive Officer and Director of RYAH Group. He has over 20 years of experience in global financial markets and entrepreneurship. Wagner has held executive roles in the United States and London. He has co-founded and built several startups from the ground up. His current licensures and degrees include FINRA Series 7, 63, 24 and 55, as well as an MBA from Fordham University. Wagner received a Certification in Innovation and Strategy from Harvard University.

RYAH Group Inc. (CSE: RYAH), closed Tuesday’s trading session at $0.03, even for the day. The average volume for the last 3 months is 218,437 and the stock's 52-week low/high is $0.015/$0.20.

Recent News

Save Foods Inc. (NASDAQ: SVFD)

The QualityStocks Daily Newsletter would like to spotlight Save Foods Inc. (NASDAQ: SVFD).

Save Foods (NASDAQ: SVFD) (FSE: 80W), an agri-food tech company specializing in eco crop protection that helps reduce food waste and ensure food safety, today announced that it is collaborating with Auryon Holdings, a strategic advisory and private equity firm, to make Save Foods’ green treatment available in Sub-Saharan Africa. Save Foods’ treatment can benefit African countries by helping to provide populations with fresher, healthier produce while also assisting African packers to meet export standards. “With a strategy in place to extend Save Foods’ global reach and to address the increased demand for our green products worldwide, our next step is to help African farmers to get better quality and more value from their crops,” said Dan Sztybel, CEO of Save Foods’ Israeli subsidiary. “We want to equip growers and packers with Save Foods treatment to minimize waste and optimize the shelf life of their crops. Also, with global supply chains still impacted by the COVID-19 pandemic, and more recently by the Ukraine crisis, improving local food supply is becoming increasingly important.” To view the full press release, visit

Save Foods Inc. (NASDAQ: SVFD) is an agri-food tech company focused on developing and selling eco-friendly products specifically designed to ensure food safety and extend the shelf life of fresh fruits and vegetables. The company is focused on addressing two of the most significant challenges faced by the industry: (1) food waste and loss, and (2) food safety.

Fungi like mold and yeast, as well as foodborne pathogens, are typically responsible for fresh produce spoilage and foodborne illness. Save Foods’ integrated solutions improve safety, freshness and quality every step of the way, from field to fork. The company’s natural products control human and plant pathogens, allowing growers, packers and food retailers to reduce waste and boost revenues. More food ends up on consumers’ plates, and less ends up in landfills.

Save Foods’ products use all-natural ingredients to protect fresh produce from microbial spoilage and pathogens with zero toxicity. The company’s treatments leave no harmful residues on produce or in the environment and maintain product freshness over time. Fresh produce treated with Save Foods’ products can already be found in supermarket chains across the U.S. and Europe. Those chains have reported that the company’s products are reducing fruit spoilage by 50% on average at the retail level. With no need for additional steps in the treatment process nor special equipment, Save Foods’ products are easy to implement and come in versatile applications suitable for the different stakeholders along the food supply chain.

Initial applications for the company’s offerings include post-harvest treatments in fruit and vegetable packing houses that process citrus, avocados, pears, bell peppers and mangos. By controlling and preventing pathogen contamination and significantly reducing the use of chemicals and their residues, Save Foods’ products not only prolong shelf life; they also ensure safe, natural and healthy food. Save Foods has the first green products that could realistically replace the different chemicals used today in food treatment while controlling waste and food safety.

Products & Technology

  • SavePROTECT or PeroStar, a processing aid added to fruit and vegetable wash water and used in post-harvest treatment;
  • SF3HS and SF3H, post-harvest treartment solutions to control both plant and foodborne pathogens;
  • SpuDefender, for controlling post-harvest potato sprouts; and
  • FreshPROTECT, for controlling spoilage microorganisms on post-harvest citrus.

Save Foods’ products are based on a proprietary blend of food acids which have a synergistic effect when combined with certain types of sanitizers and fungicides at low concentrations in a non-organic setting. The combination eliminates fungicide residues or reduces them to levels below the established Maximum Residue Levels (MRLs). The company’s fruit and vegetable wash is odorless and does not irritate human eyes, skin or airways. Save Foods’ blend does not leave any residues of toxicological concern on the treated surface of produce, and all its ingredients are classified by the U.S. Food and Drug Administration (FDA) as Generally Recognized As Safe (GRAS). There are 7 patent families related to Save Foods’ technology.


The company’s products have been commercially validated on citrus, mangos, avocados, pears, bell peppers, microgreens and various fresh cut vegetables. Save Foods is in the validation process for bananas, apples, figs, berries, lettuce, papayas and more. The company is also validating the efficacy of its products for pre-harvest treatment, starting with citrus trees.

Market Outlook

The world population is expected to grow to almost 10 billion by 2050, boosting current agricultural demand by some 50%. Providing healthy and safe food for the world’s population is one of the biggest challenges of the 21st century.

Globally, around 664 million tons of fresh fruits and vegetables are lost every year from field to fork, wasted by spoilage, and almost one in 10 people globally falls ill every year from eating contaminated food, with an estimated resulting cost around $90 billion.

Disposing of all that wasted food requires additional expense and harms the environment with resulting greenhouse gas emissions. The post-harvest food treatment market was valued at $1.5 billion in 2019 and is expected to grow to $2.3 billion by 2026, achieving a CAGR of 6.5%.

Management Team

David Palach is CEO of Save Foods. He spent over a decade with Intel Israel, where his last position was Manager of Business Development for Israel and Europe. Prior to that, he served as a controller of two of Intel’s largest factories in Israel, where he supervised a budget of over $1 billion. He also served as the CEO of B-Pure Corporation Ltd., a management and maintenance company involved in protecting and improving the environment. During his tenure, he helped turn around several struggling subsidiaries and made them profitable.

Vered Raz Avayo is the company’s CFO. Before joining SaveFoods in 2018, she spent more than 10 years as CFO at LGC, the Leviev Group of Companies. She has operated her own financial and business consultancy and has served as a director for a number of public companies in Israel.

Dan Sztybel is CEO of SaveFoods Ltd., the Israeli subsidiary of Save Foods Inc. He previously led the Life Sciences Advisory at EY Israel and early on recognized the potential of Israel as a center of innovation in the digital health space. He has been an adviser on digital health strategy to large pharmaceutical companies and is a cofounder of MyndYou, a digital health start-up focusing on cognitive impairment. He is also a co-founder of the conference, the largest digital health conference in Israel.

Dr. Neta Matis is Vice President of R&D at Save Foods Ltd the Israeli subsidiary of Save Foods Inc . She holds a Ph.D. in organic chemistry and an MBA from Tel Aviv University. Prior to joining Save Foods in 2019, she held multiple research chemist and product development roles at Verdia Inc. and its parent company, Helsinki-based Stora Enso Oyj.

Nimrod Ben Yehuda is the founder and CTO of Save Foods Ltd. He was previously the CEO/CTO of Swissteril Water Purifications Ltd. He has also been CEO at Nir Ecology Ltd., and was Joint-CEO at NitroJet Ltd.

Dr. Art Dawson is the U.S. Business Manager for SaveFoods Inc. He has been president of The Dawson Company, which focuses on creating sales opportunities for new agricultural technologies, previously Dr. Dawson held senior industry positions like General Manager Worldwide of the Decco , the Post Harvest Division for Elf Atochem. He holds a Ph.D. in Plant Physiology from UC Riverside and is licensed in California as an agricultural Pest Control Advisor.

Save Foods Inc. (SVFD), closed Tuesday’s trading session at $5.47, off by 17.2466%, on 337,841 volume. The average volume for the last 3 months is 337,841 and the stock's 52-week low/high is $3.4001/$22.00.

Recent News Inc. (NASDAQ: LTRY)

The QualityStocks Daily Newsletter would like to spotlight Inc. (LTRY). (NASDAQ: LTRY), a leading technology company that is transforming how, where and when the lottery is played, has scheduled a conference call to discuss its financial and company results for the period ended Dec. 31, 2021. The call is slated for Thursday, March 31, 2022; the call will begin at 8:30 a.m. ET. The company noted that it will release a press release outlining the company’s performance prior to the call. The call will also be broadcast live on the company’s investor relations website. Those interested in joining the call can dial 877-313-2495 in the United States or 929-517-0906 if calling from outside the U.S, then use the conference code 5886747; callers should dial in at least 15 minutes before the event begins. Following the call, a recording of the call will be available after the event ends on the company’s investor relations website. To view the live webcast, visit To view the full press release, visit Inc. (NASDAQ: LTRY) is a next generation platform where consumers can play the lottery online – in browser or via smartphone app. The platform offers users access to official lottery games sanctioned by their individual states and also provides lottery data to more than 400 digital publishers, including Google and Amazon Alexa. was founded in 2015, launching at the LAUNCH festival and soon turning into a leader in the industry. With headquarters in Austin, Texas, the company is dedicated to helping advance the lottery industry into the digital age and works closely with state regulatory bodies to achieve this goal.

The company recently entered into a definitive agreement for a business combination with special purpose acquisition company Trident Acquisitions Corp. (NASDAQ: TDAC) (“Trident”), which will result in becoming a publicly listed company. Once the transaction is complete, the combined company will be trademarked as, with its common stock to remain listed on Nasdaq under ticker symbol ‘LTRY’. Online Platform

The online platform works closely with state regulators, advancing the lottery into the digital age. With the online platform, the company offers enhanced regulatory capabilities by leveraging innovative blockchain technology and capturing the untapped market of digitally native players.

Players go online in a browser or through a mobile application to use the interface. The process includes:

  • Players Choose a Game: Players can play officially state sanctioned multi-state games and other games offered in the states in which they live. Players can also find winning numbers, jackpot totals, draw dates and more for hundreds of other lottery games around the world.
  • Players Pick Numbers: Players can play their lucky numbers or do a quick pick of randomized numbers in as simple as two taps. “Tap, Tap, Ticket!”
  • A Safe and Secure Way to Play: Purchases for up to 50 tickets can be made at one time through the online interface. handles everything after purchase, letting users know when they win.
  • Collect All Winnings: Consumers keep 100% of their winnings. All winnings stay in the balance for future ticket purchases, or a cashout can be requested. Company representatives contact winners who hit big jackpots, instructing them on the redemption process.

A Better Way to Play the Lottery has an innovative e-commerce platform that is using blockchain to maintain an accurate ledger. From 2016 to 2020, grew gross revenue at a CAGR of 363%, and it forecasts gross revenue equal to approximately $71 million in 2021, $279 million in 2022, and $571 million in 2023. is leveraging a successful playbook, with $398 billion in global lottery sales but only 6.7% online penetration. The large market opportunity is expected to shift to online transactions within the next decade.

The platform is currently available in 12 states across the United States, and the company plans to expand to 34 by the end of 2023. Global expansion is also on the horizon, with partnership plans in Turkey and Ukraine.

Key features that make the experience unique include:

  • All the Games Users Love – For consumers who live in applicable LIVE states, Powerball and Mega Millions are available right from the mobile application.
  • Convenience – makes playing the lottery on mobile devices easy. After setting up an account, users can begin playing in moments or set reminders to play when the jackpot is high.
  • Easy Cashouts – Users can cash out winnings straight to a bank account, safely and securely, with no commissions.

The company is also gamifying charitable giving, fundamentally changing how nonprofits engage with donors and raise funds. is a platform designed to offer charitable donation sweepstakes to incentivize donors to take action by offering large cash prizes and once-in-a-lifetime experiences.

Strong Advisory Board Presence is expected to continue to gain support, leaning on the experience of its advisory board and notable investors from the venture capital, gaming and entertainment industries. These include:

  • Jason Robins, CEO of DraftKings Inc. (NASDAQ: DKNG)
  • Ben Narasin, Venture Partner of NEA
  • Peter Diamandis, Chairman of XPRIZE Foundation
  • Matthew Le Merle, Co-Founder and Managing Partner of Fifth Era and Keiretsu Capital
  • Paraag Marathe, President of Enterprises and EVP of Football Operations for the San Francisco 49ers
  • Jamie Gold, The Poker Philanthropist

Management Team

Tony DiMatteo is the Co-Founder and Chief Executive Officer of He is a serial entrepreneur and highly sought-after industry speaker and thought leader. He has been featured in The Wall Street Journal, Forbes, VentureBeat, TechCrunch Inc. and more for his approach to entrepreneurship, the gaming industry and cryptocurrency.

Matt Clemenson is the Co-Founder and Chief Commercial Officer of He is responsible for the company’s strategy. Mr. Clemenson was steeped in corporate and enterprise engineering processes at Hotwire and Expedia before going on to be CEO at LesConcierges, the world’s largest concierge company, which merged into John Paul and sold to Accor Hotels. Clemenson and DiMatteo have been partners for more than 10 years.

Ryan Dickinson is the company’s President and Chief Operating Officer. He has a diverse background in business, technology, product, design and sales, which has aided him in producing many successful outcomes throughout his career. Notably, as Senior Vice President of a SaaS company, Mr. Dickinson produced profitability from a negative $1.4 million division within the first year by reinventing the product offerings, streamlining processes and establishing a go-to-market strategy. Additionally, he produced three record breaking revenue years in a row for AccuWeather, the world’s largest weather provider, by increasing every KPI for all flagship properties by no less than 5%.

Luc Vanhal is the company’s Chief Financial Officer. He has served in C-level executive roles since the 1990s, including a nine-year tenure for The Walt Disney Company (NYSE: DIS) from 1990 to 1999. From 2001 to 2004, he managed the development of the World of Warcraft massively multiplayer game, which, by the end of 2020, still had over five million active subscribers. As the CFO of, Mr. Vanhal leads the company’s global finance organization, with treasury responsibility, accounting, analysis and financial planning. Inc. (LTRY), closed Tuesday’s trading session at $3.06, off by 0.649351%, on 69,682 volume. The average volume for the last 3 months is 69,682 and the stock's 52-week low/high is $3.00/$17.50.

Recent News

Eat Well Investment Group Inc. (CSE: EWG) (OTC: EWGFF)

The QualityStocks Daily Newsletter would like to spotlight Eat Well Investment Group Inc. (CSE: EWG) (OTC: EWGFF).

Eat Well Investment Group (CSE: EWG) (OTC: EWGFF), a vertically integrated plant-based foods company, continues to build on acquisitions to solidify its position as a producer of nutritious foods with end-to-end supply chain linkage. A recent article discussing company CEO, President and Director Marc Aneed’s interview with The Bell2Bell Podcast quotes him as saying, “We’re one of the forerunners, we would say, today in solving the critical gap in the chain of plant-based foods… With a collection of astute, strategic investments … we’ve created a vertically integrated model whereby we have plant-based proteins that we process close to the farm gate, we have a food tech division that creates next-generation foods, and we actually have a branded business called Amara, which has plant-based infant nutrition-type products like baby cereals and toddler snacks.” Eat Well achieved nearly CA$60 million in revenue in 2021 despite the challenges of COVID, supply chain clogs and the relative newness of the platform. Aneed anticipates Eat Well Group continuing at a hyper-growth rate in years to come. To view the full article, visit

Eat Well Investment Group Inc. (CSE: EWG) (OTC: EWGFF), headquartered in Vancouver, British Columbia, is a publicly traded vertically integrated plant-based foods company combining the best of agribusiness, foodtech, and CPG brands to supply the world with innovative, delicious, and better-for-you foods. The company supplies Beyond Meat, Ingredion, Nestle, General Mills and more. It is on track to generate $60 million in revenue for 2021 and is projecting $100 million in revenue for 2022.

Eat Well’s management team has an extensive record of sourcing, financing and building successful companies across a broad range of industries and maintains a current investment mandate on the health and wellness industry. The team has financed and invested in early-stage venture companies for more than 25 years, resulting in the ability to construct a portfolio of opportunistic investments intended to generate superior risk-adjusted returns. Eat Well’s strategic advisory board includes pioneers in the plant-based foods industry, including HRH Prince Khaled bin Alwaleed bin Talal Al Saud, Founder and Chief Executive Officer of KBW Ventures, and Jeff Dunn, CEO of Bolthouse Farms who previously held senior leadership positions at both Campbell Soup Company and The Coca Cola Company.

The company’s plant-based investment thesis is centered on growing its seed-to-market operations, which include raw ingredients, processing, pulse fractionation, unique IP and premium consumer packaged goods (CPG). Eat Well Group is building a unique ecosystem that can supply these essential cornerstone needs for society. The company has plant-based foods and nutrition experts specializing in the latest science and original thinking for what consumers want most – high quality and affordability in healthy, clean and simple products.

Eat Well focuses on intellectual property, product portfolio development and long-term value creation for stakeholders in a rapidly expanding industry. As an emergent sector globally, plant-based foods represent a double-digit annual growth category, with more than 35% of the world’s supply of pulse proteins coming from Canada.


On July 31, 2021, Eat Well Group acquired Belle Pulses Ltd., one of the top pulse processors in Canada. Belle Pulses has been operating for over 40 years and had over $60 million in sales in 2020. The company counts a broad range of customers in over 35 countries, including global strategic food companies and major ingredient distributors. Currently, Belle produces nearly 100,000 tons of fully traceable seed and product, yielding over 26,000 tons of pure plant protein.

Eat Well also owns 100% of Sapientia Technology Inc. Led by Dr. Eugenio Bortone – one of the world’s preeminent food scientists and extrusion processing experts and the inventor of Frito-Lay’s Twisted Cheetos – Sapientia has filed four patents around the “protein curl” and crispy-puff-style snack. By focusing on texture and crunch, Sapientia’s patents solve one of the major problems that large scale snack food companies have struggled with for years – how to offer appealing texture and flavor in a guilt-free, not fried, natural and healthy alternative to the majority of snack food products available today.

Eat Well owns a 51% share of Amara Organic Foods, with an option to acquire additional ownership up to 80 percent. Amara, one of the fastest-growing baby food brands in America, is a food technology company that uses science and proprietary IP that locks in taste and texture to make healthy, organic, non-GMO, plant-based, convenient baby and children’s food possible for modern-day families. From baby food to toddler food and beyond, Amara is driven by the belief that setting kids on the right path from a young age will help them live better, feel better and think better for the rest of their lives. Amara’s revenues have grown by more than 400% since January 2021, and the brand’s success has drawn media coverage from business news outlets including Forbes and TechCrunch.

Market Outlook

According to an August 2021 report from Bloomberg Intelligence, the plant-based foods market is expected to experience explosive growth, comprising up to 7.7% of the global protein market by 2030 at a value of over $162 billion, up from $29.4 billion in 2020. Bloomberg notes that plant-based alternatives are here to stay, and that consumption will grow rapidly. Plant-based food sales in 2020 grew twice as fast as overall food sales, according to Polaris Market Research.

Pulse proteins (fava, yellow pea, etc.) are a foundational ingredient to most plant-based foods due to their high protein content and their readily available, affordable supply.

Many analysts view the food tech market as similar to the early days of the Internet in that plant-based foods represent a worldwide secular trend of steady growth and potential that will revolutionize the way society functions and people experience nutrition.

The sector continues to experience significant M&A transactions. Recently, Sol Cuisine was acquired by PlantPlus Foods LLC, a major South American protein producer, in an all-cash transaction valued at approximately $126 million, or 6x revenue.

Management Team

Marc Aneed is President and Director of Eat Well Group. His 20-year career in CPG started at The Quaker Oats Company/PepsiCo, where he worked on iconic brands like Gatorade. He previously was at Glanbia PLC, a global nutrition company, where he led Amazing Grass, a leading plant nutrition and supplement company with over $100 million in retail sales. He also led Glanbia’s Sports Nutrition brands in North America with over $750 million in retail sales. Mr. Aneed has launched dozens of successful consumer products, driving over $1 billion in collective retail sales.

Mark Coles is the company’s Chief Investment Officer. He is a veteran CPG senior executive specializing in the plant-based foods sector. For the past decade, Mr. Coles has spearheaded global plant-based start-up initiatives, culminating in a 2020 acquisition by an international New York Stock Exchange-listed food ingredient company. He has over 25 years of experience in CPG-focused strategy, mergers and acquisitions and project financing.

Patrick Dunn is Eat Well Group’s Vice President, Finance. He is the founding partner of Dunn, Pariser & Peyrot and has a track record of building highly successful agribusinesses throughout North America and other international markets. As a testimony to his business portfolio work, Mr. Dunn and his firm have won multiple industry awards for accounting, finance and business management.

Barry Didato is the company’s Vice President, Strategy. He is focused on the development of strategic revenue channels, sales partnerships, and international distribution for Eat Well Group. Mr. Didato brings extensive strategic sales capabilities and an extensive network of contacts in the industry to the company. Prior to joining Eat Well Group, he served for over 18 years as a senior advisor for several ultra-high net worth family offices and numerous innovative wellness, nutrition, medical, and food businesses.

Strategic Advisory Board

HRH Prince Khaled bin Alwaleed bin Talal Al Saud, Founder and Chief Executive Officer of KBW Ventures, is a firm supporter of clean energy and the humane treatment of animals. He is also a vocal supporter of the private sector in the Middle East. A member of the Saudi Arabian Royal Family, Prince Khaled was born in Stanford and spent his youth in Riyadh under the mentorship of his father, philanthropist HRH Prince Alwaleed bin Talal Al Saud, Chairman of Kingdom Holding Company. He is also the Founding Chairman of KBW Investments and serves across several boards. He invests in an array of successful but diverse global businesses – from promising technology startups to established companies. Today, with holdings on three continents, Prince Khaled stands at the gateway between the Middle East’s evolving economies and the Western world. Consistently, Prince Khaled’s focus is on ventures and ideas at the intersection of innovation and economic growth.

Jeff Dunn has over 30 years of experience in agriculture and packaged food, including senior leadership positions with Bolthouse Farms, Campbell Soup Company and The Coca Cola Company, among others. He is an Operating Partner at Butterfly and focuses primarily on the agriculture & aquaculture and food & beverage product sectors. Prior to joining Butterfly, Mr. Dunn was the President of the Campbell Fresh division of Campbell Soup Company from 2015 to 2016, where he was in charge of building Campbell’s scale and accelerating its growth in the rapidly expanding packaged fresh segments and categories across the retail perimeter.

Eat Well Investment Group Inc. (OTC: EWGFF), closed Tuesday’s trading session at $0.3312, off by 4.6069%, on 32,709 volume. The average volume for the last 3 months is 32,709 and the stock's 52-week low/high is $0.308/$1.00.

Recent News

Red White & Bloom Brands Inc. (CSE: RWB) (OTCQX: RWBYF)

The QualityStocks Daily Newsletter would like to spotlight Red White & Bloom Brands Inc. (OTCQX: RWBYF).

Last week, the Illinois House of Representatives approved a bill that would protect workers who use cannabis while off-duty from being terminated. The bill would also prevent employees from discriminating against job seekers who have tested positive for cannabis. The measure is currently under consideration in the Senate and includes some exemptions. The bill is sponsored by Democratic Representative Bob Morgan, who states that individual liberties should be respected. He spoke to WGEM saying that no one should be discriminated against in the workplace because of their choices as long as those choices do not impact the working environment. As more states take the step taken by Illinois to prevent cannabis consumers from being penalized for off-duty consumption, residents will be more free to buy legally produced products by companies such as Red White & Bloom Brands Inc. (CSE: RWB) (OTCQX: RWBYF) that are made for recreational or medicinal use.

Red White & Bloom Brands Inc. (CSE: RWB) (OTCQX: RWBYF) is a torchbearer blazing a new frontier in American cannabis by adhering to the highest ethical, manufacturing, educational, branding and employment standards available in the industry.

Red White & Bloom is a super state operator, leveraging a sizable footprint to dominate the areas in which it operates. CEO Brad Rogers and other management members have seen the struggles of multi-state operators who have spread themselves too thin, which is why Red White & Bloom is intent on dominating each state it enters before expanding further.

Although targeting individual states in the United States, the company is headquartered in Toronto, Canada. Red White & Bloom was established after privately held MichiCann Medical Inc. merged with publicly traded Tidal Royalty in 2019.


Red White & Bloom has entered strategic brand acquisitions and partnerships aimed at helping the company expand its presence and position as one of the largest players in the United States cannabis market. Red White & Bloom is always diligently searching for brands to acquire that will provide additional value to the company and expand its national footprint.

The company’s current brand portfolio includes:

  • Platinum Premium Cannabis Products (PV): Platinum uses innovative thinking, honesty and responsibility to remain at the forefront of the cannabis industry. PV holds itself and its partners to the highest standards, providing clean and safe CBD and THC products. In the company’s press release dated January 13, 2021, it reported system-wide sales of Platinum-branded products exceeding $2.8 million for the first week of January alone.
  • High Times®: In June 2020, the company acquired the licensing rights and branding of High Times dispensaries and High Times cannabis-based CBD and THC products in Michigan, Illinois and Florida. The company also acquired branding of High Times hemp derived CBD products nationally in the United States carrying the Culture® brand.
  • Mid-American Growers: Mid-American began as a family operation in 1971 in Granville, Illinois. The original 8-acre greenhouse has expanded to a 3.6-million-square-foot, state-of-the-art technology and science facility under glass. Mid-American’s product offerings include its CBD Icy Relief Salve, CBD Icy Relief Roll-on and CBD Gummies.

Retail Focus

Red White & Bloom is working to establish a significant retail presence across multiple jurisdictions. In Michigan, the company is invested in and has the rights to acquire (subject to regulatory approvals) a licensed operator that controls the assets of 18 dispensary locations throughout the state. Red White & Bloom is also pursuing opportunities in Florida aimed at making its proposed retail footprint compelling and attractive to the majority of cannabis consumers within each state.


Red White & Bloom is focused on standardization and quality, with everything guided by a relentless commitment to the highest standards. The company acquired a 3.6-million-square-foot standardized facility dedicated to helping it achieve premium value for the products it intends to cultivate.

As it continues to expand, the company remains committed to the practices that have guided its success in the past, including:

  • A top-down approach to cultivation developed under the guidance of PhDs with expertise in growing principles, SOPs and, most importantly, the science behind it all.
  • Commitment to exceeding the requirement of the states in which it operates. The company cut its teeth under the world’s first national cannabis purity regime – a regime that most new markets use as a benchmark – so quality is in its DNA.
  • Science-driven production methods supported by automated, perpetual, standardized operations that enable craft cannabis-like quality at an industrial scale.


Assuming completion of the currently proposed investments and acquisitions, Red White & Bloom will be among the cannabis market’s largest companies, joining the ranks of a select few multi-state operators dominating the industry. Red White & Bloom currently has assets (closed and in closing stages) in Michigan, Illinois, Florida, California, Oklahoma and Massachusetts.

The company’s strategic acquisition and super state operator model, combined with its commitment to top-quality product and service, position it to become a leading player in the North American cannabis market.

When evaluated beside competitors in the cannabis space, Red White & Bloom boasts an extremely attractive valuation. While large cap cannabis firms serving North American markets averaged enterprise-value-to-EBITDA multiples of 14.9x as of December 2020, Red White & Bloom’s enterprise multiple was just 3.4x, as noted in the company’s latest investor deck.

In 2020, the cannabis market worldwide was valued at $24.6 billion. This amount is expected to expand at a CAGR of 14.3% from 2021 to 2028, resulting in a market size of $84 billion in 2028 ( Of the 2020 valuation, the largest revenue share (91.1%) was attributed to North American consumers (

Management Team

Brad Rogers is the CEO and Executive Chair of Red White & Bloom. He is a visionary for the future of cannabis and CBD products in the United States market, with a proven track record of building successful and profitable businesses in the rapidly expanding and new economic sector. Mr. Rogers was a part of the team that built one of the first commercially scaled production facilities in the world for medicinal cannabis. He also served as President for one of the leading licensed producers in Canada. Both of his ventures were successful, with a combined market cap of $2 billion.

Michael Marchese is the company’s Co-Founder and Marketing Advisor. He has played a crucial role in its development and organization, overseeing capital raises, acquisition strategy and brand identity. Mr. Marchese has a strong reputation and presence in the cannabis industry. He also co-founded and directed the branding of Aleafia Health Inc., which he continues to counsel. Through his branded company, Marchese Design, he has served as a highly trusted counselor to top-level execs, including C-Suite level employees, offering insights into the process of creating, building and maintaining brand identities.

Theo van der Linde is the CFO and Director of Red White & Bloom. He is a Chartered Accountant with 20 years of experience in finance, administration and public accounting. The experience he has acquired spans multiple industries, including mining, oil & gas, financial services, retail and manufacturing. For the last nine years, he has primarily focused his career on the mining industry, working with junior exploration and producing mining companies at various stages of growth in several jurisdictions. Mr. van der Linde is also the current President of Executive Management Solutions Ltd.

Red White & Bloom Brands Inc. (RWBYF), closed Tuesday’s trading session at $0.2525, off by 8.0481%, on 124,940 volume. The average volume for the last 3 months is 124,940 and the stock's 52-week low/high is $0.25/$1.30.

Recent News

FuelPositive Corp. (TSX.V: NHHH) (OTC: NHHHF)

The QualityStocks Daily Newsletter would like to spotlight FuelPositive Corp. (NHHHF).

  • Russia’s invasion of Ukraine has demonstrated the harmful effects of the world’s reliance on fossil fuels, strengthening the case for replacing fossil fuels with renewable energy sources
  • The invasion has destabilized the fertilizers market, with Russia threatening to halt exports and Yara announcing a planned reduction in production
  • FuelPositive understands the importance of independence from market forces that may negatively affect consumers
  • The company is working on rolling out its green ammonia production system, with the planned launch of initial units set for this summer

Russia’s invasion of Ukraine has greatly impacted the global economy, with commodity prices soaring to all-time highs and the energy sector reeling from the ever-increasing cost of crude oil and natural gas. Described as a “needless war of choice” in a March 8 White House Fact Sheet (, the conflict has brought to light the global dependence on fossil fuels, the deleterious impacts of their curtailed supply on whole sectors, and their ability to fund and fuel wars. To that end, countries the world over are now working to avert such adverse outcomes in the future. FuelPositive (TSX.V: NHHH) (OTCQB: NHHHF) recently announced that it is on track to deliver the first prototype of its modular green ammonia production system in late summer 2022. According to company Chief Operating Officer Nelson Leite, “FuelPositive is moving forward at full speed to commercialize our in situ, modular, scalable, and transportable green ammonia production system.” Per the announcement, the building of the first demonstration units for its green ammonia production system is progressing according to plan. The system is made up of a nitrogen generator to extract nitrogen from the air, a water electrolyzer to generate hydrogen from water, and a patent-pending green ammonia synthesis reactor that will combine the hydrogen and nitrogen to form ammonia. A recent article reads: “According to the company, the electrolyzer’s construction has been completed and has passed the Factory Acceptance Testing (‘FAT’). Further, the synthesis reactor is on track for the planned demonstration pilot project, while the nitrogen generator, which experienced some delays due to pandemic-induced supply chain issues, is not expected to affect the rollout of the demonstration units planned to begin in late summer 2022. To meet this target, FuelPositive anticipates it will begin validating the systems in the first half of the year…” To view the full article, visit

FuelPositive Corp. (TSX.V: NHHH) (OTC: NHHHF) is a growth stage company focused on licensing, partnership and acquisition opportunities building upon various technological achievements. The company is committed to providing commercially viable and sustainable clean energy solutions, including carbon-free ammonia (NH3), for use across a broad spectrum of industries and applications.

FuelPositive is headquartered in Toronto, Canada.

Hydrogen Economy Problems and FuelPositive’s Carbon-Free Technology

The hydrogen economy is currently facing many challenges. Traditional NH3 manufacturing exists on a massive scale, but centralized facilities result in some of the world’s most concentrated CO2 emissions. In total, an estimated 200 million metric tonnes of NH3 are consumed each year, with greater than 80% utilized by the agricultural sector. NH3 is also being positioned as a viable alternative to fossil fuels.

FuelPositive’s flagship carbon-free ammonia technology provides an innovative solution to these environmental concerns. Developed by Dr. Ibrahim Dincer and his team, the company’s platform allows for the in-situ production of NH3 in an entirely sustainable manner, using only water, air and sustainable electricity.

The production of hydrogen is energy intensive, but it is just one variable hindering the growth of the hydrogen economy. Other hurdles include:

  • Storage – The storage of hydrogen by compression or liquification are both cost prohibitive and unsustainable.
  • Distribution – The distribution network for effective hydrogen deployment has yet to be developed, as the extreme high-pressure distribution requirements to transport hydrogen would result in enormous infrastructure costs.
  • End Use – R&D on the transportation-related end use applications for hydrogen is in its infancy, but almost any vehicle on the road today can be easily converted to run on NH3 at a considerably lower cost per mile traveled when compared to traditional fossil fuels.

A key benefit of FuelPositive’s patent-pending, first-of-its-kind carbon-free NH3 technology is its flexibility. The process allows for small, medium or large-scale production of NH3 on location, minimizing or even eliminating the challenges and volatility associated with storage and transportation to end use. As such, with an appropriately sized FuelPositive system and access to renewable energy, the end use applications for the company’s platform are nearly infinite.

Manufacturing Partnership

On May 19, 2021, FuelPositive announced its selection of National Compressed Air Canada Ltd. (“NCA”) to undertake manufacturing of the company’s Phase 2 hydrogen-ammonia synthesizer commercial prototype systems for carbon-free ammonia production.

In a news release detailing the partnership, FuelPositive CEO Ian Clifford noted, “This critical milestone for FuelPositive will confirm the broad application potential for our technology and is the backbone of our Carbon-Free Hydrogen-NH3 offering. Partnering with the knowledgeable and experienced team at NCA on this commercialization project will bring our development-stage program to life.”

Global Ammonia Market Outlook

The global ammonia market was valued at $52.71 billion in 2017 and is forecast to reach $81.42 billion by 2025, growing at a CAGR of 5.59%, according to data from Fior Markets (

The agricultural industry consumes more than 80% of global NH3. Smaller percentages can be attributed to the waste, water treatment, refrigerants, antiseptic, textile, mining and pharmaceutical industries.

One of the most polluting industries on the planet consists of conventional agribusinesses. These polluters are responsible for more greenhouse emissions per year than transportation. This is where FuelPositive’s technology is expected to be extremely beneficial.

Management Team

Ian Clifford is Director, CEO and Founder of FuelPositive Corp. He has over 25 years of experience in the fields of technology and marketing and has successfully led the company to global brand recognition through its unique energy solutions. Since 2006, Mr. Clifford has raised over $50 million in equity financing for FuelPositive. He also co-founded digIT Interactive, a full-service internet marketing company serving Fortune 500 clients, which he sold at the peak of the market in 2000.

Greg Gooch serves as a Director and President of FuelPositive. His multifaceted career in the electronics and finance industries has positioned him as a key advisor and funding partner to start-ups and new technology companies for over 40 years. Mr. Gooch has been involved with FuelPositive since its early days and has remained a significant supporter and consultant to the company over the years. He has a bachelor’s from McGill University and an MBA from the University of Western Ontario.

Dr. Ibrahim Dincer is a scientific advisor to FuelPositive and is recognized as a pioneer and international leader in the area of sustainable energy technologies. Along with his team, Dr. Dincer invented the modular carbon-free ammonia (NH3) production technology that FuelPositive is commercializing. His area of specialty covers various topics including ammonia, hydrogen energy and fuel cells; renewable energy systems; energy storage systems and applications; carbon capturing technologies, and integrated and hybrid energy systems He is currently managing an exemplary team of researchers in this commercialization project.

Marek Warunkiewicz is the company’s Communications & Branding Specialist. He brings more than 40 years of entrepreneurial expertise to the FuelPositive team, having held marketing, branding, advertising, project management and graphic design positions with various companies. Mr. Warunkiewicz has successfully created business-to-business marketing and advertising campaigns for a diverse group of clients ranging from high-tech to agriculture. He co-founded digIT Interactive and ZENN Motor Company alongside Ian Clifford.

Luna Clifford is the Director of Communications for FuelPositive. She has over 10 years of experience as a business owner and advisor, helping build and operate several successful start-up enterprises while managing complex stakeholder relationships. Ms. Clifford excels in strategic planning and team building, and she has completed extensive studies in the fields of communications and health care.

FuelPositive Corp. (NHHHF), closed Tuesday’s trading session at $0.115, off by 4.1667%, on 579,041 volume. The average volume for the last 3 months is 579,041 and the stock's 52-week low/high is $0.09/$0.326.

Recent News

Sugarmade, Inc. (OTC: SGMD)

The QualityStocks Daily Newsletter would like to spotlight Sugarmade, Inc. (OTC: SGMD).

  • A “bear run” in California’s volatile wholesale cannabis market may be over
  • “A wholesale turnaround would be welcome news for thousands of growers across the state
  • SGMD operates Nug Avenue, a cannabis delivery service located in the Los Angeles metropolitan area

As wholesale cannabis prices increase in California, cannabis companies operating in the state are already seeing improvement ( One of those companies, Sugarmade (OTC: SGMD), has set its eyes on expanding its end-market access as a central player in the growing California cannabis delivery marketplace while also developing its in-house cannabis production capacity to verticalize operations in the space.

Sugarmade, Inc. (OTC: SGMD) is a product and brand marketing company investing in operations and technologies with disruptive potential. The company is focused on collaborating with real people in real-time to identify the emerging desires and behaviors poised to unlock new opportunities and pathways for growth. Sugarmade seeks to redefine the marketplace by nurturing an innovative and compelling relationship between brand, botany and business – resulting in both undeniable consumer value and an intriguing cross-pollination of revenue sources.

The company’s core strategic plan is centered on expanding its end-market access as a central player in the growing California cannabis delivery marketplace while developing its in-house cannabis production capacity to verticalize operations in the space. Through a combination of organic growth and strategic acquisitions, Sugarmade intends to develop a full farm-to-door vertically integrated cannabis business.

Brand Portfolio

Sugarmade has investments in a number of subsidiaries with active operations in the California cannabis sector. These include:

  • NUG Avenue – Sugarmade owns a 70% stake in NUG Avenue, a cannabis delivery service based in Southern California providing hand-selected top-shelf products from Stiiizy, Kanha, PlugPlay and more.
  • BudCars – Sugarmade is an investor in cannabis delivery service of BudCars’ first operating location in Sacramento, California. BudCars is an online-shopping experience designed to provide new customers with an easy way to discover and order cannabis products within minutes.

Acquisition of Lemon Glow Company

On May 17, 2021, Sugarmade took a major step toward closing the loop on what its management team believes to be one of the most promising vertically integrated cannabis models in the thriving California market when it announced the signing of a definitive agreement for its acquisition of Lemon Glow Company Inc.

The Lemon Glow acquisition includes 640 acres of property, 32 of which have already been designated for outdoor cannabis cultivation. Per the company’s news release, the annual potential cultivation yield at the property is estimated to be approximately 4,000 pounds of dry trimmed cannabis flower per acre per year, which represents approximately 128,000 pounds, or 64 tons, of dry trimmed cannabis flower per year in total.

Notably, Sugarmade also benefits from the acquisition in terms of team capital, as Lemon Glow executive team members will stay on and become the core management team at the cannabis cultivation site, granting the operation over 30 years of cannabis cultivation experience.

“The Lemon Glow team are tremendous additions to the Sugarmade team,” Jimmy Chan, CEO of Sugarmade, commented in announcing the definitive agreement. “They have vast experience and established skills, as well as intricate knowledge of the property and its local grow context. That’s an enormous added value proposition in this deal. We look forward to bringing them on board, ramping up operations at the property, and taking key steps toward delivering on the promise of Sugarmade’s farm-to-door vision.”

Market Opportunity

The California cannabis industry has continued to record tremendous growth since voters approved a measure to legalize recreational use of the plant in 2016. According to data from MJBizDaily, California’s legal market hit $4.4 billion in sales in 2020, up from $2.8 billion in 2019 and $1.4 billion in 2018.

Those figures highlight California’s status as the largest legal cannabis market in the world. With roughly 28 million residents over the age of 21, California is more than twice the combined size of the four states (Arizona, New Jersey, Montana and North Dakota) that legalized cannabis in 2020.

The COVID-19 pandemic was a key driver in the growth of cannabis delivery services throughout the state in 2020. One California cannabis delivery firm reported a 60% increase in new delivery customer sign-ups in the 30 days following the March 13, 2020, declaration of a national emergency. As a result of this boom, tech companies in cannabis ecommerce were able to dramatically increase their market share.
Sugarmade’s continued efforts to develop a farm-to-door vertically integrated cannabis business position it to capitalize on these trends as the California cannabis industry continues to expand moving forward.


Jimmy Chan is the CEO of Sugarmade. He is an experienced business executive instrumental in growing multiple business operations with a strong expertise in international trade and banking, international manufacturing and importation. He is also the founder of, a company that revolutionized the custom-printed paper supplies subsector of the quick service restaurant industry, which merged with Sugarmade in 2014.

Sugarmade, Inc. (OTC: SGMD), closed Tuesday’s trading session at $0.0004, off by 20%, on 27,710,933 volume. The average volume for the last 3 months is 27.711M and the stock's 52-week low/high is $0.0003/$0.007.

Recent News

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers

The QualityStocks Sponsored News

The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal

The QualityStocks Sponsored News

The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal

The QualityStocks Sponsored News

The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.